Comparative Evaluation of Vehicle, Dose, and Duration-related Oxidative, Cardiotoxic, Inflammatory and Histologic Responses of Chromium 6+ and Doxorubicin in Rats’ Heart

Comparative Evaluation of Vehicle, Dose, and Duration-related Oxidative, Cardiotoxic, Inflammatory and Histologic Responses of Chromium 6+ and Doxorubicin in Rats’ Heart | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article Comparative Evaluation of Vehicle, Dose, and Duration-related Oxidative, Cardiotoxic, Inflammatory and Histologic Responses of Chromium 6 + and Doxorubicin in Rats’ Heart Onyedikachi,Uchechi Bliss, Egbuonu, Anthony Cemaluk Chinedum, and 3 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-2847266/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract Doxorubicin (Dox) is cardiotoxicity is established while chromium 6 + compound (Cr[VI]) could be cardiotoxic due to its bioaccumulation capacity. This study compared vehicle, dose, and duration-related oxidative, cardiotoxic, inflammatory and histologic responses of Cr[VI] and Dox intoxication in rats’ heart by standard protocols. The rats were respectively intoxicated with Cr [VI] and Dox in 3 different phases. In the first phase, sixty rats were assigned to six groups of ten each. Group 1 served as the Control while groups 2, 3, and 4 were treated with oral doses of 10, 20, and 30 mg/kg body weight (b.wt) of K 2 Cr 2 O 7 (Cr[VI]) solution while groups 5 and 6 received intraperitoneal administration of 15 and 20 mg/kg b.wt Dox for two days, respectively, before the sacrifice. The procedure was repeated in the second and third Phases, but for 60 days. Oxidative, cardiotoxic, inflammatory and histologic indices were determined in the rats’ heart. The results indicated that exposure to either Dox or Cr{VI] caused a significant ( P < 0.05) dose, vehicle and duration-dependent decrease in Superoxide dismutase (SOD), Glutathione peroxidase (GPx), Catalase (CAT) activities and Nitric Oxide(NO) levels but an increase in Cardiac Troponin (CTnI) levels, Creatinine-kinase (CK-MB), C-reactive protein(CRP), Aspartate-transaminase(AST), Lactate-dehydrogenase (LDH) and Malondialdehyde (MDA) compared to the control. Heart histopathology of Dox- and Cr[VI] treated rats showed dose, vehicle and duration-dependent pulmonary oedema, hyaline necrosis and displacement of adjacent myocytes compared to control. Thus, Cr[VI] compared well with Dox in cardiotoxicity induction accompanied with oxidative stress, inflammatory and histo-hepatic responses in the rats’ heart. Toxicology Chromium 6+ Cardiotoxicity Doxorubicin Potassium dichromate Figures Figure 1 Figure 2 Figure 3 Figure 4 Figure 5 Figure 6 Figure 7 Figure 8 Figure 9 1.0 Introduction Chromium pollution is a severe threat to man and the entire ecosystem. Several researchers deduce the indiscriminate release of Cr [VI] compounds during industrial activities like photo production, chrome plating, paint making, welding, electroplating, and leather tanning as the major ways of Cr-pollution in the ecosystem (Garcia-nino et al. ,2015; Onyedikachi et al.,2018; Onyedikachi et al., 2019; Hashem et al., 2020 ; Wuri et al., 2022 ; Fagundes et al. 2022 . Firoozichahak et al.,2022). Cr (VI) toxicity has been implicated in various Organ toxicities like respiratory, gastrointestinal, hepatic, renal, neurological, and reproductive systems. It alters general development, causes increased ROS production which limits the activities of antioxidant enzymes, protein oxidation, and DNA damage (Bagchi et al., 2002 , Awasthi et al.,2018; Husain & Mahmood, 2018 ; OEHHA, 2009; ATSDR, 2012; Remy & Clay, 2014 ; Garcia-Nino et al. , 2015; Onyedikachi et al., 2019; De Almeida et al., 2021 ). The health effects of Cr, like other trace elements and chemicals of concern, may vary with the route of exposure, possibly, through inhalation, dermal contact, and ingestion of contaminated water and food crops grown in Cr-polluted soils (Onyedikachi et al., 2019; Das et al., 2021 ; Prasad et al., 2021). Chromium (Cr) has varying oxidation states and solubility, the trivalent [Cr (III)] and hexavalent [Cr (VI)] forms (Carvalho et al., 2014 , Homa et al., 2016 , John, B.V., 2019). However, the Cr (VI) forms are more hazardous to health because they make up very strong oxidizing agents that get absorbed easily across the membranes through non-specific anion carriers (Pokhrel, G. R.& Pokhre, G. 2022)). Many studies have revealed that cardiotoxicity may occur due to exposure to drugs, toxic metals, and other unknown causes (Guven et al.,2018). Cardiotoxicity results in myocardial and electrophysiology dysfunctions which affects the heart ability to pump blood efficiently resulting in various co-morbidities and deaths ((Tabassum et al., 2015; Mladěnka et al.,2018; Erbaş et al.,2022). Doxorubicin, an established cardiotoxic agent, is a broad-spectrum antitumor drug used to treat various cancers but could lead to cardiac failure and cardiomyopathies even after treatment cessation ((Hardaway, 2019 ; Abdelatty et al.,2021; Morelli et al.,2022). The early damage occurs 1 to 3 days after drug administration, often resulting in apoptosis, necrosis, oxidative stress, which results in irreversible cardiotoxicity (Hardaway, 2019 ). The molecular mechanisms of DOX-induced cardiotoxicity are unclear. Although, the suggestive possible mechanisms of action of DOX include DOX-mediated attack on the mitochondria, increase in reactive oxygen species, iron ferroptosis, disruption of calcium homeostasis, topoisomerase dysregulation and elevation in cardiac enzymes AST, LDH and CK–MB, and Troponin (Fernandez-Chas et al., 2018 ; Al-Malky et al.,2019; Morelli et al., 2022 ). Previously, high levels of Cr 6+ were detected in soils and food crops grown around industrial areas in the South East of Nigeria (García-Niño et al.,2015; Onyedikachi etal., 2019). This could indicate high level of Cr[VI] contamination and possible health risks. The dearth of information on the cardio toxic effect of Cr (VI) compounds and also, the growing concerns of possible cardio-related ailments observed among the residents and industrial workers in the areas (García-Niño et al.,2015; Onyedikachi etal., 2019, OEHHA, 2009; NIOSH, 2013 ; Das et al.,2015; Nur-E-Alam et al.,2020) warranted the present study aimed to evaluate and compare the vehicle, dose, and duration-based oxidative, cardiotoxic, inflammatory and histologic responses of administration of Cr (VI) (as potassium dichromate) and Dox in adult male Wistar rats’ heart. 2.0 Material And Methods 2.1 Chemicals and Drugs Potassium dichromate (K 2 CR 2 O 7 ) was obtained from Sigma Chemical Co.(St. Loius, MO, USA). Doxorubicin and sterile water (Pfizer Drugs, USA) were purchased from Grace and Mercy Pharmacy, Umuahia, Nigeria. All other reagents were of analytical grade and were purchased from British drug houses (Poole, Dorset, UK). 2.2 Animal Husbandry A total of one hundred and eighty adult male Wistar albino rats (age:12week and body weight:120–140 g) reared at the animal house, College of Veterinary Medicine, Michael Okpara University of Agriculture were used for this study. The animals were housed in well-ventilated plastic cages at the College of Natural Sciences, Michael Okpara University of Agriculture, Umudike, and subjected to a photoperiod of 12h light 12h dark cycle. They were allowed access to rat chow and drinking water ad libitum for 14 days. All investigations involving the experimental animals were strictly followed regarding the guidelines for the care and use of animals as defined by the National Institute of Health Committee on Care and Use of Laboratory Animals, Institute of Laboratory Animal Resources, USA (ILAR ( 1986 ).The experiment protocols were performed after the ethical approval was granted by the College of Natural Science, Research Ethics Committee (CREC/002/21), Michael Okpara University of Agriculture. 2.3. Experimental Design Sixty (60) rats in three groups were used for each phase of treatment. The treatment phases include an acute exposure phase and two chronic exposure phases. In the I st phase (acute phase exposure), group 1, control rats received an equal volume of normal drinking water orally for 21 consecutive days while groups 2, 3 and 4 rats were respectively orally treated (using Gavage) with 10 mg/kg, 20 mg/kg and 30 mg/kg body weight of K 2 Cr 2 O 7 [Cr(VI)] compound for 21 consecutive days. Groups 5 and 6 rats respectively intraperitoneally received 15 mg/kg and 20 mg/kg body weight of doxorubicin (2 days before sacrifice). The protocol in the 2nd phase (chronic phase exposure) was as in the 1st phase but lasted for sixty (60) consecutive days. In the 3rd phase (chronic food supplementation phase), group 1, control rats were fed with a standard pellet diet and received an equal volume of distilled water. Group 2 rats received 0.01% of K 2 Cr 2 O 7 [Cr(VI)] compound in feed i.e 10mg/kg of K 2 Cr 2 O 7 [Cr(VI)] compound per kg body weight in 100g of Rat feed for 60 days. Group 3 rats received 0.02% of K 2 Cr 2 O 7 [Cr(VI)] compound in feed i.e 20mg/kg of K 2 Cr 2 O 7 [Cr(VI)] compound per kg body weight in 100g of Rat feed for 60 days. Group 4 rats received 0.03% of K 2 Cr 2 O 7 [Cr(VI)] compound in feed i.e 30mg/kg of K 2 Cr 2 O 7 [Cr(VI)] compound per kg body weight in 100g of Rat feed for 60 days. Group 5 and 6 rats respectively received intraperitoneal administration of 15 mg/kg and 20 mg/kg body weight of doxorubicin (2 days before sacrifice). The doses of K 2 Cr 2 O 7 used in this study were based on the pilot study and as previously published (Navya et al.2018; Adjroud, 2009 ) while doses of, and methods used for, Dox administration were based on earlier published reports (Radwan et al., 2012 ; Biondo, 2016; Sandamali et al.,2019; Karabulut et al., 2021 and Furihata et al.,2021). 2.4 Preparation of heart samples All analyses, including biochemical and histopathology assessment of heart tissue carried out in the first phase, were repeated in the second and third phases. On the 22nd and 61st day, i.e., after overnight fasting. Ketamine injection was administered intraperitoneally to anaesthetize the animals, followed by prompt excision of the respective rats’ heart tissues. Part of the heart was rinsed in normal saline. One gram was weighed, sliced, and ground with laboratory mortar and pestle in a 5ml phosphate buffer solution. The resulting solution was centrifuged at 2200rpm for 25minutes in a cold centrifuge at 4 0 c. The supernatant (homogenate) was collected, labelled, and preserved in the freezer until analysis. The heart homogenates were used to assess CK-MB, CRP, AST, LDH, and Trop. Also, part of the heart was excised and fixed in 10% buffered formalin for a histopathology examination. 2.4.1 Body Weight and Relative Organ Weight The body weight of each rat in the groups was weighed at the beginning of the study and on the day of sacrifice. The excised organs (heart) were weighed during the sacrifice to calculate the relative organ weight(using the formula below) and observed for gross lesions. $$Relative organ weight =\frac{Organ weight \left(g\right) of animal on sacrifice day \left(g\right) }{Body weight \left(g\right) of animal on sacricice day } X 100$$ 2.5 Biochemistry Assay SOD activity was assayed by the method of Arthur and Boyne ( 1985 ). GP X assay was carried out according to the method of Paglia and Valentine (1967). The activity of Catalase was assayed by the method of Sinha ( 1972 ). Lipid peroxidation product (MDA) was assayed according to the method described by Wallin (1993). LDH assay was carried out according to the method used by Jung (2000). CK-MB assay was carried out according to the method of Henry (1974). AST assay was according to the method of Reitman and Frankel ( 1975 ). NO assay was also carried out according to the method described by Dessy and Ferron ( 2004 ). Spectrophotometric reading was assessed using D3900 UV-VIS Spectrophotometer (Hach TechnologiesLoveland USA.) 2.6 Immuno Assays The Troponin test (CTnI) was carried out according to the method of Melanson (2007). C-reactive proteins (CRP) were analyzed using the method of Anderson and Mccarthy ( 1950 ) as determined using commercially available ELISA kits following the procedure described in the manual. 2.7 Preparation of slides for histopathological evaluation The hearts of the rats were isolated immediately after sacrifice, washed with cold phosphate-buffered saline (pH = 7.4) and fixed in 10% buffered formalin. Tissues were embedded in paraffin, and 5m serial sections of the heart were taken. These sections were stained with Hematoxylin and Eosin (H&E). Changes in the histopathology were observed under a light microscope (Olympus BX10, Tokyo, Japan), and images were taken using a digital camera. The individual performing the evaluation was blinded to the treatment given to the respective groups. Tissue sections of the heart were collected for histopathological studies. Prior to the commencement of tissue preparation, the heart samples were fixed in formalin (10% buffered) after washing with cold phosphate-buffered saline (7.4). The tissues were prepared by trimming and dehydrating in 70%, 80%, 90%, and absolute alcohol, clearing in 3 grades of xylene, and solidifying the tissues in molten wax. On solidifying, the tissue-containing wax blocks were cut into 5µm thick sections with a rotary microtome, floated in a water bath, and incubated at 60 ˚ C for 30 minutes. The 5µm thick sectioned tissues were cleared in 3 grades of xylene and rehydrated in 3 grades of alcohol (90%, 80%, and 70%). The sections were then stained with Hematoxylin for 15 minutes. Blueing was done with ammonium chloride, and differentiation was done with 1% acid alcohol before counterstaining with Eosin. Permanent mounts were made on degreased glass slides using a mountant, DPX. The prepared slides were examined with a Motic™ compound light microscope using x4, x10, and x40 objective lenses. The photomicrographs were taken using a Motic™ 5.0 megapixels microscope camera at x400 magnifications. 2.8 Statistical Analysis The least significant difference (LSD) was used to compare differences in each sample within treatments. Data were reported as mean ± Standard Error (SE). One-way analysis of variance (ANOVA) was also used to determine significant differences between groups, considering a level of significance of less than or equal to ( P < 0.05) by using SPSS. The significant difference was assessed using Duncan at ( P < 0.05). 3.0 Result 3.1 Absolute and Relative Heart Weight The absolute and relative heart weights of rats treated orally (by administration with Gavage) with K 2 Cr 2 O 7 for 21 days are presented, respectively, in Appendix 1. The experimental rats' absolute and relative heart weights indicated no significant difference compared to the Control (p < 0.05). However, a slight increase in the absolute and relative heart weight of groups treated with K 2 Cr 2 O 7 for 60days was observed compared to the Doxorubicin and Normal (Control) groups for all treatment routes. 3.2 Different doses of K 2 Cr 2 O 7 and Doxorubicin impaired Antioxidant enzymes following acute and chronic exposure to Rats in the Treatment Phases (Phase 1, 2 and 3). Results presented in Fig. 1 (A, B and C) show that rats exposed to K 2 Cr 2 O 7 and Dox respectively elicited a significant (p < 0.05) decrease in GPx, CAT, and SOD activities in the treatment phases relative to the control (Group 1). In phase 1,The SOD activities decreased by 0.89%,10.62%, 24.78% K 2 Cr 2 O 7 treated Rats, CAT activities also decreased by 30.86%,42.23% and 48.03% in K 2 Cr 2 O 7 treated rats, likewise, GPx activities decreased by 12.96%, 21.96% and 34.01% in rats treated with 10mg/kg, 20mg and 30mg/kg K 2 Cr 2 O 7 respectively, relative to the normal control animals. Similarly, animals treated with 15mg/kg and 20mg/kg Dox in groups 5 and 6 showed decreased GPx, CAT, and SOD activities. The percentage decreases in the enzyme activities for groups 5 and 6 relative to the control group were 2.65% and 4.24%(SOD), 0.23% and 18.33%(CAT), and 34.4% and 12.55%(GPx). In the Second phase, the SOD activities decreased by 20%, 22.5%, 39.17% in K 2 Cr 2 O 7 treated rats, CAT activities also decreased by 19.34%, 30.82% and 45.62% in K 2 Cr 2 O 7 treated rats. Likewise, GPx activities decreased by 2.70%, 21.95% and 30.62% in Rats treated with 10mg/kg, 20mg and 30mg/kg K 2 Cr 2 O 7 respectively relative to the Normal control animals. Similarly, animals that received 15mg/kg and 20mg/kg Dox) in Groups 5 and 6 showed decreased GPx, CAT, and SOD activities by 10.38% and 14.17%, 1.81%, and 9.37%, 5.42%, and 8.40% respectively compared to the enzyme activities recorded for the Normal Control(Group 1). In the Third Phase, the SOD activities decreased by 2.90%, 11.63%, and 22.67% K 2 Cr 2 O 7 in treated Rats. CAT activities also decreased by 4.04%, 40%, and 45% in K 2 Cr 2 O 7 treated rats. Likewise, GPx activities decreased by 26.92%, 35.49% and 38.11% in Rats treated with 10mg/kg, 20mg and 30mg/kg K 2 Cr 2 O 7 respectively relative to the normal control animals. Similarly, animals treated with 15mg/kg and 20mg/kg Doxorubicin (Dox) in Groups 5 and 6 decreased the enzyme activities by 30.81% and 32.56% (SOD), 1.21% and 3.24%(CAT), and 27.27% and 27.47% (GPx) compared to the normal Control(Group 1). 3.3 Treating rats with different doses of K 2 Cr 2 O 7 and Dox induced Oxidative Stress in all the treatment phases (First, Second and Third Phases). The results presented in Fig. 2 shows the level of MDA investigated in the hearts of the Control, K 2 Cr 2 O 7, and Dox treated Rats. The Rats that received both K 2 Cr 2 O 7 and Dox showed a significant increase in MDA levels following the First, Second and Third treatment Phases when compared to the Normal Control, the percentage increase in MDA levels for the Rats treated with 10mg/kg, 20mg/kg, and 30mg/kg K2Cr2O7 was 16.67%, respectively, 63.33%, 90.00%, respectively, in the first phase. In the second phase, the MDA levels increased significantly by 46%, 151.47%, and 368.38% compared to the levels observed in the Control. Similarly, the percentage increases observed compared to Control for the third treatment phases were 18.55%, 23.39% and 33.87% for 10mg/kg, 20mg/kg, and 30mg/kg K 2 Cr 2 O 7 respectively. In the Dox groups (5 and 6), the Rats treated indicated similar spike increases (p < 0.05) in the levels of MDA compared to the levels observed in the Control. The percentage increases were 3.33% and 40% (First Phase), 2.21% and 27.94%(Second phase), and 26.61% and 28.23% (Third Phase) for Rats treated with 15mg/kg and 20mg/kg Dox treated groups respectively. 3.4 Rats treated with different doses of K 2 Cr 2 O 7 and Dox showed increased Cardiac markers (AST, LDH, and CK-MB) activities in the first treatment phase. Results presented in Fig. 3 (A, B and C) show that rats exposed to K 2 Cr 2 O 7 and Dox respectively elicited a significant (p < 0.05) increase in AST, LDH, and CK-MB activities in the treatment phases relative to the control (Group 1). In the phase 1 , AST results indicated 22.53%, 37.56%, and 64.39% increases in enzyme activities. LDH activities also increased by 55.24%, 73.82%, and 116.10%. Also, CK-MB activities followed the increasing trend by 16.46%, 45.60%, and 87.63% for Rats treated with 10mg/kg, 20mg/kg, and 30mg/kg K 2 Cr 2 O 7, respectively, when compared to the Control group. Similarly, the rats treated with 15mg/kg and 20mg/kg Dox in groups 5 and 6 indicated increased AST, LDH, and CK-MB activities. The percentage increases in activities for groups 5 and 6 compared to the control group were 2.65% and 4.24% (AST), 0.23% and 18.33%(LDH), and 34.4% and 12.55%(CK-MB). In the second phase, the AST results indicated 30.76%, 38.73%, and 93.56% increases in enzyme activities. LDH activities also increased by 34.37%, 47.17%, and 70.25%. Also, CK-MB activities followed the increasing trend by 33.15%, 58.80%, and 101.12% for Rats treated with 10mg/kg, 20mg/kg, and 30mg/kg K 2 Cr 2 O 7, respectively, when compared to the Normal group. Likewise, the rats treated with 15mg/kg and 20mg/kg Doxorubicin(Dox) in groups 5 and 6, respectively, indicated increases in AST, LDH, and CK-MB activities. The percentage increases in activities for groups 5 and 6 compared to the control group were 5.28% and 4.56%(AST), 38.33% and 56.43%(LDH), and 9.71% and 18.13%(CK-MB). In the third phase, the AST results indicated 12.35%, 25.20%, and 33.89% increases in enzyme activities. LDH activities also increased by 3.56%, 10.32%, and 13.48%. Also, CK-MB activities followed the increasing trend by 8.55%, 25.48%, and 101.12% for Rats treated with 10mg/kg, 20mg/kg, and 30mg/kg K 2 Cr 2 O 7, respectively, when compared to the Normal group. Similarly, the rats treated with 15mg/kg and 20mg/kg Doxorubicin (Dox) in groups 5 and 6, respectively, showed elevated levels of AST, LDH, and CK-MB activities. The percentage increases in activities for groups 5 and 6 compared to the control group were 5.28% and 4.56% (AST), 38.33% and 56.43%(LDH), and 9.71% and 18.13%(CK-MB). 3.5 Rats treated with different doses of K 2 Cr 2 O 7 and Dox increased Cardiac Troponin-I(CTnI) levels in all the treatment phases(First, Second and Third Phases). The results in Fig. 4 shows the levels of CTnI investigated in the hearts of the Control, K 2 Cr 2 O 7, and Dox − treated Rats with a significant increase in CTnI levels in all the treatment Phases. The percentage increase in CTnI levels for the Rats treated with 10mg/kg, 20mg/kg, and 30mg/kg K 2 Cr 2 O 7 compared to the Normal Control was 29.18%, 35.01%, 38.91% for the first phases. In the second phase, the CTnI levels increased significantly by 63.76%, 65.07%, and 71.62% compared to the levels observed in the Control. Also, the percentage increases observed compared to Control for the third treatment phase were 2.28%, 3.33% and 9.52% for 10mg/kg, 20mg/kg, and 30mg/kg K 2 Cr 2 O 7 respectively. In the Dox groups(5 and 6), the Rats treated indicated similar increases(p < 0.05) in the levels of CTnI compared to the levels observed in the Control. The percentage increases were 4.67% and 15.57% (First Phase), 20.09% and 10.48%(Second phase), and 3.81% and 4.77% (Third phase) for Rats treated with 15mg/kg and 20mg/kg Dox treated groups respectively. 3.6 Rats treated with different doses of K 2 Cr 2 O 7 and Dox indicated increased C-Reactive Proteins (CRP) in all the treatment phases (First, Second and Third Phases). Results presented in Fig. 5 shows spikes in C- Reactive Protein levels compared to Control, K 2 Cr 2 O 7, and Dox treated Rats. The percentage increase in CRP levels for the Rats treated with 10mg/kg, 20mg/kg and 30mg/kg K 2 Cr 2 O 7 compared to the normal Control were 35.62%, 45.21%, 82.19% for the first phases. In the second phase, the CRP levels increased significantly by 113%, 229%, and 300% compared to the observed control values. Also, the percentage increases observed compared to Control for the third treatment phases were 2.56%, 9.29% and 18.27% for 10mg/kg, 20mg/kg, and 30mg/kg K 2 Cr 2 O 7 respectively. In the Dox groups(5 and 6), the Rats treated indicated similar spike increases(p < 0.05) in the levels of CRP compared to the levels observed in the Control. The percentage increases were 23.28% and 23.29% (First Phase), 38% and 114%(Second phase), and 2.56% and 7.05% (Third phase) for Rats treated with 15mg/kg and 20mg/kg Dox treated groups respectively. 3.7 Different doses of K 2 Cr 2 O 7 and Dox inhibited Nitric Oxide levels in the heart of treated Rats in all phases(First, Second and Third Phases). Results presented on Fig. 6 shows decreases in the levels of NO availability in the hearts of K 2 Cr 2 O 7 and Dox-treated rats compared to the Control. The percentage decrease in NO levels for the Rats treated with 10mg/kg, 20mg/kg, and 30mg/kg K 2 Cr 2 O 7 compared to the normal Control were 4.65%, 18.61%, 27.91% for the first phase. Conversely, in the second phase, NO indicated an increase of 31.7%, 41.7%, and 76.8% compared to the Control. Also, percentage increases were observed compared to control for the third treatment phases were as follows: 385%, 885% and 1200% for 10mg/kg, 20mg/kg, and 30mg/kg K 2 Cr 2 O 7, respectively. The NO levels in Dox groups (5 and 6) in the first phase indicated a slight decrease compared to control levels. In contrast, a significant increase (p < 0.05) was observed in the levels of NO in the second and third phases compared to the Control. The percentage decreases were 2.31% and 4.65% (First Phase), while the percentage increase was 19.5% and 1.22% (Second phase), and 750% and 1115% (Third Phase) for Rats treated with 15mg/kg and 20mg/kg Dox treated groups respectively. 3.8: The effect of administering K 2 Cr 2 O 7 and Doxorubicin intraperitoneal injection on the myocardial histoarchitecture of animals treated in the first phase (H&E X400) representative photomicrographs followed by light microscopy are indicated as follows: Histopathology result shows Alphabeths a-f representing various photomicrographs of the treatment groups in phase one (21 days). (a) depicts Control rats that received an equal volume of normal drinking water orally for 21 consecutive days, (b) Rats that received oral administration of 10 mg/kg body weight of K 2 Cr 2 O 7 [Cr(VI)] compound for 21 consecutive days, (c) Rats that received oral administration of 20 mg/kg body weight of K 2 Cr 2 O 7 [Cr(VI)] compound for 21 consecutive days, (d) Rats that received oral administration of 30 mg/kg body weight of K 2 Cr 2 O 7 [Cr(VI)] compound for 21 consecutive days, (e)15 mg/kg body weight doxorubicin (2 days prior to sacrifice) administered intraperitoneally,(f)20 mg/kg body weight doxorubicin (2 days prior to sacrifice) administered intraperitoneally. 3.9 Effect of K 2 Cr 2 O 7 and Doxorubicin in phase 2 histopthology results H and E X400, representative photomicrographs followed by light microscopy are indicated as follows: Fig 8 shows Alphabeths g-l representing various photomicrographs of the treatment groups in phase one(60 days). (g) Control rats that received an equal volume of normal drinking water orally for 60 consecutive days, (h) rats that received oral administration of 10 mg/kg body weight of K 2 Cr 2 O 7 [Cr(VI)] compound for 60 consecutive days, (i) Rats that received oral administration of 20 mg/kg body weight of K 2 Cr 2 O 7 [Cr(VI)] compound for 60 consecutive days, (j) Rats that received oral administration of 30 mg/kg body weight of K 2 Cr 2 O 7 [Cr(VI)] compound for 60 consecutive days, (k) Rats given 15 mg/kg body weight doxorubicin (2 days prior to sacrifice) administered intraperitoneally,(l) rats given 20 mg/kg body weight doxorubicin (2 days prior to sacrifice) administered intraperitoneally. 3.10: Effect of K 2 Cr 2 O 7 and Doxorubicin in phase 3 on the myocardial histoarchitecture of animals treated in the Third phase using the H&E staining E X400, representative photomicrographs followed by light microscopy are indicated as follows: The effect of treatment groups was represented using Alphabeths m-r on Fig. 9 shows m Control rats fed a standard pellet diet and received an equal volume of distilled water, n shows Rats given 0.01% of K 2 Cr 2 O 7 [Cr(VI)] compound in feed, i.e., 10mg/kg of K 2 Cr 2 O 7 [Cr(VI)] compound per Kg Bodyweight in 100g of Rat feed for 60 days, o shows Rats given 0.02% of K 2 Cr 2 O 7 [Cr(VI)] compound in feed, i.e., 20mg/kg of K 2 Cr 2 O 7 [Cr(VI)] compound per Kg Bodyweight in 100g of Rat feed for 60 days, p shows Rats given 0.03% of K 2 Cr 2 O 7 [Cr(VI)] compound in feed, i.e., 30mg/kg of K 2 Cr 2 O 7 [Cr(VI)] compound per kg Bodyweight in 100g of Rat feed for 60 days, q shows Rats given 15 mg/kg body weight Dox (2 days prior to sacrifice) administered intraperitoneally, r shows Rats given 20 mg/kg body weight doxorubicin (2 days prior to sacrifice) administered intraperitoneally. 4.0 Discussion Many research data indicate that environmental exposure to Toxic metals is implicated in the severe pathogenesis of chronic diseases. In this present study, there was no mortality during the treatment phases. The rats also showed increased final body weights across groups, as seen in Tables 1 . However, we observed a statistically marked increase in body weight of the control groups compared to those that received K 2 Cr 2 O 7 and Dox. There was also a significant difference in the relative heart weight of rats fed K 2 Cr 2 O 7 compared to the absolute heart weight of the Control and Dox-treated rats. It was also noted that as the concentration of K 2 Cr 2 O 7 administered increased, reduced relative heart weight was observed in the experimental Rats. K 2 Cr 2 O 7 intoxication may have been responsible for the rats' observed relative heart weight reduction. This finding agrees with (Soudani et al., 2011 ), where severe toxicity to brush border enzymes was observed by K 2 Cr 2 O 7 intoxication. Likewise, (Hayyan et al., 2016 ) and (Wuri et al., 2022 ) have also buttressed K 2 Cr 2 O 7 toxicity in kidneys and oocytes of exposed rats suggesting that oxidative damage may be responsible for the reduced relative organ weight. Table 1 Effect of K 2 Cr 2 O 7 and Doxorubicin on the body weight, absolute and relative heart weights of rats (g). Heart Weight Body Weight Absolute Relative Final Initial Control Acute exposure 0.52 ± 0.03 0.36 ± 0.04 145.69 ± 1.42 131.4 ± 1.51 Chronic Exposure 0.57 ± 0.03 0.33 ± 0.06 168.73 ± 1.48 126.4 ± 1.75 Chronic exposure in food. 0.54 ± 01 0.34 ± 0.02 161.73 ± 0.03 133.40 ± 0.03 10mg/kg Cr Acute exposure 0.51 ± 0.05 0.36 ± 0.02 140.80 ± 1.52 127.25 ± 1.32 Chronic Exposure 0.58 ± 0.05 0.37 ± 0.02 156.80 ± 2.66 138.25 ± 1.84 Chronic exposure in food. 0.60 ± 0.01 0.38 ± 0.01 156.73 ± 0.02 132.28 ± 0.02 20mg/kg Cr Acute exposure 0.53 ± 0.10 0.37 ± 0.02 141.75 ± 3.50 121.75 ± 2.91 Chronic Exposure 0.55 ± 0.10 0.35 ± 0.02 155.75 ± 3.56 137.75 ± 3.58 Chronic exposure in food. 0.47 ± 0.03 0.29 ± 0.01 161.43 ± 0.02 132.55 ± 0.01 30mg/kg Cr Acute exposure 0.54 ± 0.12 0.38 ± 0.01 141.23 ± 2.51 130.75 ± 0.80 Chronic Exposure 0.59 ± 0.12 0.38 ± 0.01 153.23 ± 3.97 135.75 ± 0.85 Chronic exposure in food. 0.59 ± 0.01 0.37 ± 0.12 160.25 ± 0.03 136.20 ± 0.02 15mg/kg dox Acute exposure 0.53 ± 0.06 0.37 ± 0.02 144.50 ± 2.00 122.40 ± 1.14 Chronic Exposure 0.58 ± 0.06 0.38 ± 0.01 159.50 ± 2.73 126.40 ± 1.24 Chronic exposure in food. 0.47 ± 0.02 0.30 ± 0.13 156.43 ± 0.02 135.70 ± 0.02 20mg/kg dox Acute exposure 0.55 ± 0.07 0.38 ± 0.01 143.5 ± 2.17 120.10 ± 1.20 Chronic Exposure 0.57 ± 0.07 0.35 ± 0.01 163.5 ± 2.15 124.00 ± 1.68 Chronic exposure in food. 0.47 ± 0.01 0.30 ± 0.01 156.15 ± 0.03 132.83 ± 0.01 Each value represents the mean ± SE; Values are significantly different at P < 0.05. It was also deduced in this study that the Cr6 + exposure through the administration of K 2 Cr 2 O 7 in all the treatment phases induced oxidative damage to the heart, as evident in the decrease of antioxidants activities (SOD, CAT, and Gpx). The antioxidant enzymes assessed in this study, as seen in Fig. 1 (A), revealed a statistically marked decrease in the antioxidant activities of GPx, SOD and CAT in phase 1 compared to the Normal Control. Also, animal groups treated with Dox showed a significant decrease in GPx, SOD, and CAT compared to the control group. These enzymatic antioxidants are the primary defence blocks that mop out the toxicity effect of the overwhelming oxidant production arising from K 2 Cr 2 O 6 and Dox exposure. The weak antioxidant defences in the heart make it a porous target compared to other organs (Abarikwu et al., 2016 ; Boriskin et al.,2020; Ankita et al., 2019 Sharifi-Rad et al.,2020). Hence, SOD, CAT, and GPx activities are impaired, resulting in cellular lipids, proteins, and DNA damage and the onset of many chronic diseases. Also, the trend of Oxidant production was observed to be on the increase as the concentrations of both K 2 Cr 2 O 6 and doxorubicin treatments increased, resulting in a decrease in the antioxidant enzyme activities (GPx, CAT, and SOD) due to the overwhelming burden of the toxic agents (Boriskin et al.,2020; Wuri et al.2022). In Phase 2, the antioxidant enzymes shown in Fig. 1 (B) indicated a similar trend in the decreased SOD, CAT, and GPx activities of the rats exposed to different doses of K 2 Cr 2 O 7 and Dox for 60days. The percentage decrease in the enzyme activities was higher than the decrease observed in the first treatment phase. This may result from the longer duration of the animal exposure to K 2 Cr 2 O 7 , compromising the antioxidant defence system and resulting in cardio-damages (Krishnamurthy et al. ,2015; Abarikwu et al., 2016 ; Ankita et al.,2019; Sharifi-Rad et al.,2020; Fagundes et al.,2022). Similarly, Phase 3 presented in Fig. 1 (C) shows a decrease in the antioxidant activities of GPx, SOD and CAT in rats treated with different doses of K 2 Cr 2 O 7 supplemented in diets and Dox for 60days. The percentage decrease in antioxidant enzymes observed in rats in the second phase of treatment by oral gavage administration was significantly higher than in the third phase by diet supplementation (Foster et al.,2015). Our findings agree with (Foster et al.,2015), whose results propose that bolus gavage administration of manganese could be associated with higher brain manganese levels and, consequently, a higher risk of neurotoxicity. Therefore, this present study suggests that the higher cardiotoxicity effect observed in the oral Gavage- K 2 Cr 2 O 7 treated rats compared to the supplemented diet- K 2 Cr 2 O 7 treated rats may be responsible for the higher decreased antioxidant activities. These observations have raised concerns regarding the fitness of oral treatment administration using Gavage against diet supplementation due to the endocrine disruptor effects observed by the gavage method (Vandenberg et al., 2014 ; Foster et al.,2015). Secondly, the increased MDA levels observed in all the phases in this present study, as evident in Fig. 2 , further reiterate that Rats' treatment with different doses of K 2 Cr 2 O 7 and Dox induced oxidative stress. The prevalence of MDA in Cr(VI) treated rats is attributable to lipid peroxidation and an increase in ROS production induced by the K 2 Cr 2 O 7 treatments, thus degrading polyunsaturated lipids or fatty acids in the rats' perturbed biological system; hence may be responsible for the increased levels of MDA observed in this study (Farrokhian et al., 2019 ; Anam & Purwanto,2020).Also, Dox has proven to generate cardio-dysfunctions through the induction of free radicals such as oxyanions, hydroxyl, and hydrogen peroxide (Teraoka et al., 2000 ; Bhardwa et al. , 2011; Hardik et al., 2013 ). Hence, increased MDA levels were observed. Researchers have also elucidated the elevation of Cardiac markers such as AST, LDH, CK–MB used as indicators of myocardial tissue damage. These includes ischemia and infarction (Wagner,2003; Yang et al., 2014 ; Fernandez-Chas et al., 2018 ; Al-Malky et al.,2019, Lakhani et al.,2021; Firoozichahak et al., 2022 ). Figure 3 (A) in this present study indicated the Cardiotoxicity of K 2 Cr 2 O 7 and Dox exposure as evidenced in the increased LDH, AST, and CK-MB activities in the phase 1 compared to the control rats. The increased levels observed may be associated with severe Cardiotoxic symptoms such as chest pain, hypertension, decreased heart function, myocarditis, cardiomyopathy, shortness of breath, arrhythmias, palpitations, vascular disease, acute coronary syndrome, oedema, and vasculitis (Gaze 2007 ; Ganatra et al.,2019; Mehta et al., Patel et al.,2021; Firoozichahak et al., 2022 ). Similar results were also observed in our findings in both the second treatment phase (Fig. 3 (B)) and the Third treatment phase (Fig. 3 (C). There was a significant percentage increase in LDH, AST and CK-MB activities of the K 2 Cr 2 O 7 treated rats in the gavage-treated and diet-supplemented rats relative to the control group. However, the percentage increase was higher in the former, probably indicating that longer treatment with different doses of K 2 Cr 2 O 7 and Dox exposed the Rats to progressive Cardiotoxicity. The higher increase observed in the myocardial markers may be due to the mode of treatment administration, which suggested severe cardiotoxicity induction through gavage administration (Foster et al.,2015; Zhai et al.,2019). Furthermore, CTnI, a quintessential and highly sensitive cardio-biomarker consisting of regulatory proteins controlling the calcium-mediated interaction of myosin and actin during myocyte contraction (Park et al., 2017 ; Chen et al.,2019, Chaulin, 2021 ). Figure 4 in this present study indicates a higher percentage increase in levels of CTnI in all the treatment phases relative to the control groups. The percentage increase progressed with increased duration of the K 2 Cr 2 O 7 exposure, i.e., 21days and 60days, respectively, compared to the control rats. The Dox groups similarly showed an increase in CTnI, indicating that both K 2 Cr 2 O 7 and Dox may be implicated in a dose and duration-dependent cardiotoxicity. CTnI changes in concentration levels are useful in diagnosing heart failure and other related cardiac diseases (Magnussen & Blankenberg., 2018). Clinical evidence has shown that patients who are often readmitted due to heart failure are those with persistent CTnI increases (Magnussen & Blankenberg., 2018). Similarly, CRP levels in this present study, as shown in Fig. 5 , indicated spikes in its levels in K 2 Cr 2 O 7 and Dox-treated rats in all the phases compared to the control groups. However,the percentage increases were significantly elevated in the second and third phases, possibly due to the longer treatment duration compared to the first phase. CRP are pro-inflammatory markers produced by the liver and used clinically to diagnose heart failure. Research pieces of evidence support that there may have occurred intestinal hypoperfusion due to the translocation of K 2 Cr 2 O 7 oral administration from the stomach into the bloodstream resulting in vascular inflammation and subsequent increased levels of CRP observed in this study (Anand et al., 2005 ; Magnussen & Blankenberg, 2018 ; Vulesevic et al.,2019). Also, in this present study, Fig. 6 indicated significant decreases in the levels of NO availability in the hearts of the K 2 Cr 2 O 7 and Dox treated Rats in the first phase compared to the normal Control. In contrast, an increase was observed in the second and third treatment phases. Many research findings has stated that NO is synthesized by a family of nitric oxide synthases with three isoforms, which include inducible (iNOS), neuronal (nNOS), and endothelial NOS (eNOS). While iNOS is upregulated in activated macrophages, nNOS is primarily expressed in the neural tissue, and eNOS abounds in the endothelium, diffuses to the smooth muscles and enables the endothelial vascular homeostasis, which controls dilation or constriction through the activation of soluble guanylyl cyclase-cGMP-dependent protein kinase pathway. In addition, the impairment of NO synthesis is pertinent in the diagnosis of chronic heart failure, coronary artery diseases, arteriosclerosis involving stable and unstable angina and myocardial infarction hypertension, and as well pulmonary arterial hypertension, which progresses to the right ventricle failure ( Ferlito, 2000 ; Silva-Costa-Gomes; Dunham-Snary et al. 2017 ; Frump et al., 2018 ; Kurakula et al.,2021 Finkelman et al.,2017; Tran et al.,2022). The discrepancy observed in NO levels in all treatment phases compared to the normal Control may be due to an overexpression of iNOS, whose induction occurs primarily in conjunction with infection and inflammation as part of the defence response. iNOS expression is minimal under normal conditions; however, it is upregulated in response to pro-inflammatory cytokines and thus generates much more NO than eNOS does. Hence, High NO levels may have occurred in response to inflammation due to K 2 Cr 2 O 7 exposure for 60 days, while the decrease in NO levels in the groups treated with K 2 Cr 2 O 7 and Dox may have resulted from the inhibition of eNOS expression due to treatment exposure for 21 days. Thus, signalling cardiotoxicity owing to the development of systemic and pulmonary hypertension, which plays a key role in the pathophysiology of heart-related ailments (Wu et al., 2021 ). Furthermore, the increase in NO levels in the DOx treated groups as seen in this study, especially in the second and third phases, indicates an upregulation of nitric oxide synthase activities as observed by other researchers leading to an increase in the concentration of nitric oxide, thereby enhancing the production of the highly toxic peroxynitrite (Wu et al., 2021 ). A report by Lee et al.(2016) has shown that NOS can play compensatory roles in laboratory animals with one or two disrupted isoforms. For example, the up-regulation of nNOS expression compensated the non-expression of eNOS and vice versa. These strides promises a useful research tool to enhance a discreet interpretation of discrepancies in NO availability and disease prognosis. The histopathological examination in Fig. 7 shows the Effect of K 2 Cr 2 O 7 treatment in phase 1, revealing control rats(a) as having the normal histoarchitecture of the heart, as the myocardium showed a rich network of vasculature, capillaries, nucleus, and pericytes. In contrast, the groups treated with K 2 Cr 2 O 7 (b, c and d) indicated areas of mild tissue oedema due to treatments exposure suggesting the pathogenesis of lung oedema due to K 2 Cr 2 O 7 induced Cardiotoxicity resulting from pulmonary hypertension from hypoxic pulmonary vasoconstriction induced by Cr(VI) agents resulting in congestive heart failure ( Dunham-Snary et al. 2017 ). The Dox groups (e and f) showed a higher degree of cardiac damage as there was myotocytolysis and hyaline necrosis in addition to pulmonary oedema, the affected cells' loss of striation, fragmentation of the myocytes, intense eosinophilic staining of the sarcoplasm (myocytes cytoplasm) with nuclear pyknosis and karyorrhexis. In group 6, oedema seemed to be more severe and widespread. Similarly, Figs. 8 and 9 revealed the histopathology examination of K 2 Cr 2 O 7 and Dox treated Rats in phase 2 and 3 showing Control groups (g and m, respectively) expressed a normal heart structure while (h, I, j) and (n, o, p) indicated areas of myocyte displaced, indicating pulmonary oedema; Dox groups (k and l) and (q and r) similarly showed areas of pulmonary oedema, hyaline necrosis and myocytolysis for the second and third study, respectively. Pulmonary oedema has been of interest to cardiologists, and pulmonologists, due to its prevalence in the onset of heart diseases. Pulmonary oedema is induced by the movement of fluid extravascularly into the interstitium and alveoli of the lungs. The most common causes of pulmonary oedema are Cardiomyopathy, Aortic valve disease, coronary heart disease, hypertension, mitral valve disease,` and congestive heart disease. Other causes include damage to the lungs, kidneys, pancreas, drugs, trauma, and toxins toxins (Ingbar, D. H.,2019; Logan et al.,2019., Barile, 2020 Moreno-Gonzalez et al.,2022).. Furthermore, Many researchers categorized pulmonary oedema into permeability oedema (with and without diffuse alveolar damage (DAD), hydrostatic pressure oedema, and mixed oedema, where there is both an increase in membrane permeability and hydrostatic pressure (Paone et al.,2018; Zompatori et al., 2014 ; Barile, 2020 ; Matthay et al., 2019; Carlicchi et al., 2021 ; Ingbar, D. H. ( 2019 ). However, it is not clear which physiologic category of the pulmonary oedema observed in this study due to the K 2 Cr 2 O 7 treatments. Conclusion Thus, this study demonstrated that Cr [VI] compared well with Dox in cardiotoxicity induction with accompanying oxidative stress, inflammatory and histo-hepatic responses in the rats. The dose and duration of treatments for the biochemical and myocardial indices are not dependent on body weight alone, hence may need pharmacokinetic modifications for conversion between animals and humans. Also, the mechanism that resulted in pulmonary oedema regarding the myocardial indices observed in this study is unclear warranting further studies for clarification. Declarations Funding The authors did not receive support from any organization for the submitted work. Financial interests The authors declare they have no financial interests. Competing Interest The authors have no competing interests to declare that are relevant to the content of this article. Ethics approval and consent to participate All investigations involving the experimental animals adhered strictly to the guidelines for the care and use of animals as defined by the National Institute of Health Guide for the Care and Use of Laboratory Animals. Committee on Care and Use of Laboratory Animals, US Department of Health and Human Services, Public Health Service, Institute of Laboratory Animal Resources, USA. The experiment protocols were performed after the ethical approval was granted by the College of Natural Science, Research Ethics Committee (CREC/002/21), Michael Okpara University of Agriculture. Consent for publication Not applicable Availability of data and material All data generated or analyzed during this study are included in this published article. Any further reasonable request can be made through the corresponding author. Authors' contributions Conceptualization: Onyedikachi, Uchechi Bliss, Awah, Favour Matthew; Kpobari Nkpaa, Methodology: Onyedikachi Uchechi Bliss, Kpobari Nkpaa, Egbuonu Anthony Cemaluk Chinedum; Awah Favour Matthew Formal analysis and investigation: Onyedikachi,Uchechi Bliss, Awah Favour Matthew; Writing - original draft preparation: Onyedikachi Uchechi Bliss; Awah Favour Matthew.; Writing - review and editing: Onyedikachi Uchechi Bliss; Ijioma,Solomon Nnah ;Egbuonu, Anthony Cemaluk Chinedum; Resources: Onyedikachi,Uchechi Bliss; Awah, Favour Matthew.; Supervision: Egbuonu, Anthony Cemaluk Chinedum, Ijioma, Solomon Nnah. References Abarikwu, S. O.,Duru, Q. C.Chinonso, O. V and Njoku, R.C. (2016). Antioxidant enzymes activity, lipid peroxidation, oxidative damage in the testis and epididymis, and steroidogenesis in rats after co-exposure to atrazine and ethanol. Andrologia, 48(5): 548-557. Abdelatty, A., Ahmed, M. S., Abdel-Kareem, M. A., Dmerdash, M., Mady, R., Saad, A. S., Albrakat, A, Elmahallawy,E. K, Elsawak, A & Abdo, W. (2021). Acute and Delayed Doxorubicin-Induced Myocardiotoxicity Associated with Elevation of Cardiac Biomarkers, Depletion of Cellular Antioxidant Enzymes, and Several Histopathological and Ultrastructural Changes. Life , 11 (9), 880. doi: 10.3390/life11090880. Adjroud, O. (2009).effects of potassium dichromate on haematological parametrs in female and male Wistar albino rats. Ass. University Bulletin of Environmental Research 12 (2), 87-98. Agency for Toxic Substances and Disease Registry.ATSDR. (2012). Toxicological profile for chromium. US Public Health Service, Agency for Toxic Substances and Disease Registry. 592. Ahmad, M. K., Syma, S., & Mahmood, R. (2011). Cr (VI) induces lipid peroxidation, protein oxidation and alters the activities of antioxidant enzymes in human erythrocytes. Biological trace element research , 144 (1), 426-435. Al-Malky, H.S., Osman, A.M., Damanhouri, Z.A., Alkreathy, H.M., Al Aama, J.Y., Ramadan, W.S., Al Qahtani, A.A., Al Mahdi, H.B. (2019). Modulation of doxorubicin-induced expression of the multidrug resistance gene in breast cancer cells by diltiazem and protection against Cardiotoxicity in experimental animals. Cancer Cell International, 19, 191. doi: 10.1186/s12935-019-0912-0. Anam, SC & Purwanto, B. (2020). Acute response moderate intensity treadmill training on decrease malondialdehyde in obesity women. STRADA Jurnal IImiah Kesehatan , 9 (2), 358-367. Anand, I. S., Latini, R., Florea, V. G., Kuskowski, M. A., Rector, T., Masson, S., ... & Cohn, J. N. (2005). C-reactive protein in heart failure: prognostic value and the effect of valsartan. Circulation , 112 (10), 1428-1434. Anderson, H.C. & Mccarthy, M. (1950). Determination of C-reactive protein in the blood as a measure of the activity of the disease process in acute rheumatic fever. The American Journal of Medicine , 8 (4),445-455. Ankita, N., Liang-jun, Y., chanda,K. J, Nilanjana, D.(2019). Role of Catalase in oxidative stress and age associated degenerative diseases. 2019:9613090 Arivarasu, N. A., Fatima, S., & Mahmood, R. (2008). Oral administration of potassium dichromate inhibits brush border membrane enzymes and alters antioxidant status of rat intestine. Archives of toxicology , 82 (12), 951-958. Arthur, J. R and Boyne, R. (1985). Superoxide dismutase and glutathione peroxidase activities in neutrophil from selenium deficient and copper deficient cattle. Life Sciences , 36, 1569-1575. Awasthi, Y., Ratn, A., Prasad, R., Kumar, M., & Trivedi, S. P. (2018). An in vivo analysis of Cr6+ induced biochemical, genotoxicological and transcriptional profiling of genes related to oxidative stress, DNA damage and apoptosis in liver of fish, Channa punctatus (Bloch, 1793). Aquatic toxicology , 200 , 158-167. Bagchi, D., Stohs, S & Downs, B. (2002). Cytotoxicity and oxidative mechanisms of different forms of chromium. Toxicology, 180:5–22. https://doi.org/10.1016/s0300-483x(02)00378-5 Barile M. (2020). Pulmonary Oedema: A Pictorial Review of Imaging Manifestations and Current Understanding of Mechanisms of Disease. European journal of radiology open , 7 , 100274. https://doi.org/10.1016/j.ejro.2020.100274 Bhardwaj, A., Singh, S., Srivastava, S. K.Honkanen, R. E., Reed, E and Singh, A. P. (2011). Modulation of Protein Phosphatase 2A Activity Alters Androgen-Independent Growth of Prostate Cancer Cells: Therapeutic Implications. Molecular Cancer Therapy , 10 , 720–731. Biondo, L.A., Lima, J.E.A., Souza, C.O., Cruz, M.M., Cunha, R.D.C., Alonso-Vale, M.I., Oyama, L. M., Nascimento, C. M. O., Pimentel,G.D., dos Santos, R.V. T. , Lira, F. S., Neto, J C. R. (2016). Impact of Doxorubicin Treatment on the Physiological Functions of White Adipose Tissue. PLoS ONE, 11 (3): e0151548. doi:10.1371/journal.pone.0151548 Boriskin, P., Gulenko, O., Devyatkin, A., Karimova, R., Leonov, V., & Pavlova, O. (2020). Correlation of the distribution of antioxidant enzyme concentrations in blood serum and heart tissue in rats. In BIO Web of Conferences, EDP Sciences (Vol. 17, p. 00234). DOI:10.1051/bioconf/20201700234 Carlicchi, E., Gemma, P., Poerio, A., Caminati, A., Vanzulli, A., & Zompatori, M. (2021). Chest-CT mimics of COVID-19 pneumonia—a review article. Emergency Radiology , 28 (3), 507-518.s Carvalho, F. A.,Burgeiro, R., Garcia, A., Moreno, R. and Carvalho, P. O. (2014). Doxorubicin-induced Cardiotoxicity: from bioenergetic failure and cell death to cardiomyopathy. Medical Research Review . 34, 106–135. doi: 10.1002/med.21280 Chaulin, A. M. (2021). Elevation mechanisms and diagnostic consideration of cardiac troponins under conditions not associated with myocardial infarction. Part 1. Life , 11 (9), 914. Chen, Y., Tao, Y., Zhang, L., Xu, W., & Zhou, X. (2019). Diagnostic and prognostic value of biomarkers in acute myocardial infarction. Postgraduate medical journal , 95 (1122), 210-216. Das, A. C., Sultana, R and Sultana, M. S. (2015).Impact of tannert on worker''sreproductivehealth in the area of Hazaribagh in Dhaka, Bangladesh. International Journal Research . 2(6), 159-181. Das, P. K., Das, B. P., & Dash, P. (2021). Chromite mining pollution, environmental impact, toxicity and phytoremediation: a review. Environmental Chemistry Letters , 19 (2), 1369-1381. DOI: 10.1007/s10311-020-01102-w De Almeida, R. P., Ferrari, R. G., Kato, L. S., Hauser-Davis, R. A., & Conte-Junior, C. A. (2021). A Systematic Review on Metal Dynamics and Marine Toxicity Risk Assessment Using Crustaceans as Bioindicators. Biological Trace Element Research , 1-23. Dessy, C. & Ferron, O. (2004). Pathophysiological Roles of Nitric Oxide: In the Heart and the Coronary Vasculature. Current Medical Chemistry – Anti- Inflammatory and Anti-Allergy Agents in Medicinal Chemistry , 3 (3), 207– 216. Dunham-Snary, K. J., Wu, D., Sykes, E. A., Thakrar, A., Parlow, L. R., Mewburn, J. D., Parlow, J.L., Archer, S. L. (2017). Hypoxic pulmonary vasoconstriction: from molecular mechanisms to medicine. Chest , 151 (1), 181-192. doi: 10.1016/j.chest.2016.09.001. El-Demerdash, F. M., El-Sayed, R. A., & Abdel-Daim, M. M. (2021). Rosmarinus officinalis essential oil modulates renal toxicity and oxidative stress induced by potassium dichromate in rats. Journal of Trace Elements in Medicine and Biology , 67 , 126791. Erbaş, O., Altuntaş, İ., Çağlar, Ö., Özyilmaz, E., Sari, E., Üzümcü, İ., & Erbakan, K. (2022). Experimental Model of Cardiotoxicity. In (Ed.), Risk Factors for Cardiovascular Disease. IntechOpen . https://doi.org/10.5772/intechopen.101401 Fagundes, B. H. F., Nascimento, P. C., Aragão, W. A. B., Chemelo, V. S., Bittencourt, L. O., Eiró-Quirino, L., Silva, M.C.F., Freire, M.A.M., Fernandes, L.M.P., Maia, C.S.F., Crespo-Lopez, M. E., Lima, R. R. (2022). Methylmercury exposure during prenatal and postnatal neurodevelopment promotes oxidative stress associated with motor and cognitive damages in rats: an environmental-experimental toxicology study. Toxicology reports , 9 , 563-574. https://doi.org/10.1016/j.toxrep.2022.02.014 Farrokhian, A., Raygan, F., Soltani, A., Tajabadi-Ebrahimi, M., Sharifi Esfahani, M., Karami, A. A., & Asemi, Z. (2019). The effects of synbiotic supplementation on carotid intima-media thickness, biomarkers of inflammation, and oxidative stress in people with overweight, diabetes, and coronary heart disease: A randomized, double-blind, placebo-controlled trial. Probiotics and antimicrobial proteins, 11(1), 133-142. Ferlito, S.(2000). Cardiovascular diseases and nitric oxide in humans. Minerva Cardioangiol. Nov; 48 (11),379-86. Fernandez-Chas, M., Curtis, M.J., Niederer, A.S. (2018). Mechanism of Doxorubicin cardiotoxicity evaluated by integrating multiple molecular effects into a biophysical model. Br. J. Pharmacol ., 175 , 763–781. Finkelman, B. S., Putt, M., Wang, T., Wang, L., Narayan, H., Domchek, S., ... & Ky, B. (2017). Arginine-nitric oxide metabolites and cardiac dysfunction in patients with breast cancer. Journal of the American College of Cardiology , 70 (2), 152-162. doi: 10.1016/j.jacc.2017.05.019 Firoozichahak, A., Rahimnejad, S., Rahmani, A., Parvizimehr, A., Aghaei, A., & Rahimpoor, R. (2022). Effect of occupational exposure to lead on serum levels of lipid profile and liver enzymes: An occupational cohort study. Toxicology reports , 9 , 269-275. doi: 10.1016/j.toxrep.2022.02.009. Foster, M.L., Bartnikas, T.B., Johnson, L.C., Herrera, C., Pettiglio, M.A., Keene, A.M., Taylor, M.D., Dorman, D.C. ( 2015). Pharmacokinetic evaluation of the equivalency of Gavage, dietary, and drinking water exposure to manganese in F344 rats. Toxicological Science, 145(2),244-51. https://doi.org/10.1093/toxsci/kfv047 Frump, A. L., Bonnet, S., de Jesus Perez, V. A., & Lahm, T. (2018). Emerging role of angiogenesis in adaptive and maladaptive right ventricular remodeling in pulmonary hypertension. American Journal of Physiology-Lung Cellular and Molecular Physiology , 314 (3), L443-L460. DOI: 10.1152/ajplung.00374.2017 Furihata, T., Maekawa, S., Takada, S, Kakutani, N., Nambu, H., Shirakawa, R., Gad, S. C. (2015). Cardiovascular toxicology and its evaluation. Mammalian Toxicology , 425-452. https://doi.org/10.1002/9781118683484.ch19 Ganatra S, Parikh R, Neilan, T.G.(2019). Cardiotoxicity of immune therapy. Cardiol Clin. , 37(4), 385–97. https://doi.org/10.1016/j.ccl.2019.07.008. García-Niño, W. R.,Zatarain-Barrón, Z. L.,Hernández-Pando, R.,Vega-García, C. C.Tapia, Eand Pedraza-Chaverri, J. (2015). Oxidative Stress Markers and Histological Analysis in Diverse Organs from Rats Treated with a Hepatotoxic Dose of Cr(VI): Effect of Curcumin. Biological Trace Element and Research. , 167(1), 130-45. https://doi.org/10.1007/s12011-015-0283-x Gaze, D. C. (2007). The role of existing and novel cardiac biomarkers for cardioprotection. Current Opinion in Investigational Drugs, 8 (9), 711-717. Gutteridge, J. M. (1995). Lipid peroxidation and antioxidants as biomarkers of tissue damage. Clinical Chemistry, 41 (12 Pt 2), 1819-1828. Guven, C., Sevgiler, Y., & Taskin, E. (2018). Mitochondrial dysfunction associated with Doxorubicin. Mitochondrial Disease , 323 . DOI: 10.5772/intechopen.80284. Hardaway,B.W (2019). Adriamycin-associated cardiomyopathy: where are we now?updates in pathophysiology, dose recommendations, prognosis, and outcomes. Current Opinion Cardiology. 34, 289–295. Hardik, G., Vaibhav, B., Patel, N. M., Naeem, P.,Jatin, N and Ramachandran, B. (2013). Doxorubicin mediated Cardiotoxicity in rats: Protective role of felodipine on cardiac indice. Environmental Toxicology and Pharmacology, 36, 787–795. Hashem, M. M., Abo-EL-Sooud, K., Abd-Elhakim, Y. M., Badr, Y. A. H., El-Metwally, A. E., & Bahy-El-Dien, A. (2020). The long-term oral exposure to titanium dioxide impaired immune functions and triggered cytotoxic and genotoxic impacts in rats. Journal of Trace Elements in Medicine and Biology , 60 , 126473. https://doi.org/10.1016/j.jtemb.2020.126473 Hayyan, M., Hashim, M. A and Al Nashef, I. M. (2016). Superoxide Ion: Generation and Chemical Implications. Chemical Review. 116 (5): 3029–385. Henry, J. B. (1979). Clinical Diagnosis and Management by Laboratory Methods W.BSa under sand Company, Philadelphia, Page 365 (1979). Homa, D., Haile, E and Washe, A. P. (2016). Determination of spatial chromium contamination of the environment around industrial zones. Inter Journal of Analytical Chemistry , Article ID 7214932. https://doi.org/10.1155/2016/7214932 Husain, N., & Mahmood, R. (2018). 3, 4-Dihydroxybenzaldehyde quenches ROS and RNS and protects human blood cells from Cr (VI)-induced cytotoxicity and genotoxicity. Toxicology in Vitro , 50 , 293-304. ILAR (1986). Guide for the Care and Use of Laboratory Animals. Committee on Care and Use of Laboratory Animals, US Department of Health and Human Services, Public Health Service, Institute of Laboratory Animal Resources, USA. Ingbar, D. H. (2019). Cardiogenic pulmonary oedema: mechanisms and treatment-an intensivist's view. Current opinion in critical care , 25 (4), 371-378. Jung, K., Nickel, E, & Pergande, M. (2000). A micro-albuminuria assay using bromphenol blue. ClinicaChimica Acta , 187 , 163-172. Karabulut, D., Ozturk, E., Kaymak, E., Akin, A.T., Yakan, B. (2020).Thymoquinone attenuates doxorubicin‐cardiotoxicity in rats. Journal of Biochemical and Molecular Toxicology, 20s20(e22618), 1-9 Kurakula, K., Smolders, V. F., Tura-Ceide, O., Jukema, J. W., Quax, P. H., & Goumans, M. J. (2021). Endothelial dysfunction in pulmonary hypertension: cause or consequence?. Biomedicines , 9 (1), 57. Lakhani, H. V., Pillai, S. S., Zehra, M., Dao, B., Tirona, M. T., Thompson, E., & Sodhi, K. (2021). Detecting early onset of anthracyclines-induced Cardiotoxicity using a novel panel of biomarkers in West-Virginian population with breast cancer. Scientific Reports , 11 (1), 1-11. doi: 10.1038/s41598-021-87209-8 Lee, J., Bae, E. H., Ma, S. K., & Kim, S. W. (2016). Altered nitric oxide system in cardiovascular and renal diseases. Chonnam Medical Journal , 52 (2), 81-90. https://doi.org/10.4068/cmj.2016.52.2.81 Logan, D., Rubayat, R., Mohamed, E., Pablo, P., Nugent,K., (2019). Cardiogenic Pulmonary Oedema, Am J Med Sci., 358 (6),389-397. doi: 10.1016/j.amjms.2019.09.011. Magnussen, C. & Blankenberg, S. (2018). Biomarkers for heart failure: small molecules with high clinical relevance. Journal of internal medicine , 283 (6), 530-543. Matthay, M. A., Zemans, R. L., Zimmerman, G. A., Arabi, Y. M., Beitler, J. R., Mercat, A., ... & Calfee, C. S. (2019). Acute respiratory distress syndrome. Nature reviews Disease primers , 5 (1), 1-22. Mehta, L. S., Watson, K. E., Barac, A., Beckie, T. M., Bittner, V., Cruz-Flores, S., Dent, S., Kondapalli, L., Ky, B., Okwuosa, T., Piña, I.L., Volgman, A. S. (2018). Cardiovascular disease and breast cancer: where these entities intersect: a scientific statement from the American Heart Association. Circulation , 137 (8), e30-e66. DOI: 10.1161/CIR.0000000000000556 Melanson, S. E.,Tanasijevic, M. J & Jarolim, P. (2007). Cardiac Troponin assay. Circulation , 116 (18), e501-504. Mladěnka, P., Applová, L., Patočka, J., Costa, V. M., Remiao, F., Pourová, J., Mladěnka, A., Karlíčková, J., Jahodář, L., Vopršalová, M., Varner, K.J., Štěrba, M., TOX‐OER and CARDIOTOX Hradec Králové Researchers and Collaborators. (2018). Comprehensive review of cardiovascular toxicity of drugs and related agents. Medicinal research reviews , 38 (4), 1332-1403. doi: 10.1002/med.21476 Mookerjee, A., Basu, J. M., Majumder, S., Chatterjee, S., Panda, G. S., Dutta, P., ... & Choudhuri, S. K. (2006). A novel copper complex induces ROS generation in doxorubicin resistant Ehrlich ascitis carcinoma cells and increases activity of antioxidant enzymes in vital organs in vivo. BMC cancer, 6(1), 1-11. Morelli, M. B., Bongiovanni, C., Da Pra, S., Miano, C., Sacchi, F., Lauriola, M., & D’Uva, G. (2022). Cardiotoxicity of Anticancer Drugs: Molecular Mechanisms and Strategies for Cardioprotection. Frontiers in Cardiovascular Medicine , 9 . https://doi.org/10.3389/fcvm.2022.847012. Moreno-Gonzalez, G., & Toapanta-Gaibor, N. D. (2022). Non Invasive Ventilation in Acute Cardiac Pulmonary Oedema . In Teaching Pearls in Noninvasive Mechanical Ventilation (pp. 305-314). Springer, Cham. Navya, K., Phani, K.G., Chandrasekhar, Y., Anilakumar, Kr. (2018) Evaluation of Potassium Dichromate (K2Cr2O7)-Induced Liver Oxidative Stress and Ameliorative Effect of Picrorhiza kurroa Extract in Wistar Albino Rats. Biological Trace Element Research 184 (1):154-164. doi: 10.1007/s12011-017-1172-2. NIOSH (2013). Criteria for a recommended standard occupational exposure to hexavalent chromium. CDC - US Department of Health and Human Services and Centers for Disease Control and Prevention NIOSH - National Institute for Occupational Safety and Health. 168. Nur-E-Alam, M., Mia, M. A. S, Ahmad, F and Rahman, M. M.(2020).An overview of Chromium removal techniques from tannery effluents. Appl Water Sci. 10,205. Office of Environmental Health Hazard Assessment (OEHHA). (2009) Evidence on the developmental and reproductive toxicity of chromium (hexavalent compounds). Reproductive and Cancer Hazard Assessment Section. Office of Environmental Health Hazard Assessment. 977. Onyedikachi, U. B., Achi, N. K., Oriaku, C. E. & Onyeabo, C. (2019a).Health risk assessment of heavy metal contamination of some indigenous vegetables grown in oil spilled agricultural area in Ogoniland, rivers state, Nigeria. Nigerian Agricultural Journal , 52 (1),138-151. Onyedikachi, U. B.,Belonwu, D. C and Wegwu, O. M. (2018). Human health risk assessment of heavy metals in soils and commonly consumed food crops from quarry sites located at Isiagwu, Ebonyi State. Ovidius University Annals of Chemistry, 29, 8-24. https://doi.org/10.2478/auoc-2018-0002 Onyedikachi, U. B.,Belonwu, D. C and Wegwu, O. M. (2019b). Health risk assessment of Chromium, Manganese and Arsenic through the consumption of food from Industralized areas in South Eastern, Nigeria. Annual Research and Review in Biology , 31(6), 1 - 20. DOI: 10.9734/arrb/2019/v31i630067 Pagilia, D.E., & Valentine, W N. (1967). Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. Journal of Laboratory and Clinical Medicine , 70, 158-69. .https://doi.org/10.5555/URI:PII:0022214367900765 Paone, G., De Rose, G., Giudice, G. C., & Cappelli, S. (2018). Physiology of pleural space after pulmonary resection. lung , 17 , 20. Park, K. C., Gaze, D. C., Collinson, P. O., & Marber, M. S. (2017). Cardiac troponins: from myocardial infarction to chronic disease. Cardiovascular research , 113 (14), 1708-1718. Pokhrel, G. R., & Pokhre, G. (2022). The Effect of Chromium on Human-Health: A Review. BMC Journal of Scientific Research , 5 (1), 27-35. Prasad, S., Yadav, K. K., Kumar, S., Gupta, N., Cabral-Pinto, M. M., Rezania, S., ... & Alam, J. (2021). Chromium contamination and effect on environmental health and its remediation: A sustainable approaches. Journal of Environmental Management , 285 , 112174. DOI: 10.1016/j.jenvman.2021.112174 Radwan, R. R., Shaban, E. A., Kenawy, S. A., & Salem, H. A. (2012). Protection by low-dose γ radiation on doxorubicin-induced nephropathy in rats pretreated with curcumin, green tea, garlic or l-carnitine. Bulletin of Faculty of Pharmacy, Cairo University, 50(2), 133-140. Reitman, S. & Frankel, S. (1975). Acolorimetric method for the determination of serum glutamic oxaloacetic and glutamic pyruvic transaminases. American Journal of Clinical Pathology , 28 , 56-63. Remy, L. L., & Clay, T. (2014). Longitudinal analysis of health outcomes after exposure to toxics, Willits California, 1991–2012: application of the cohort-period (cross-sequential) design. Environmental Health , 13 (1), 1-11. https://doi.org/10.1186/1476-069X-13-88 Sandamali, J. A. N., Hewawasam, R. P., Jayatilaka, K. A. P. W., Mudduwa, L. K. B. (). Dose dependent cardiac effects of Doxorubicin in wistar rats: A Biochemical and histopathological analysis. International Journal of Pharmaceutical Sciences and Research , 10 (6), 2700-2710. DOI: 10.13040/IJPSR.0975-8232.10(6).2700-10 Sharifi-Rad, M., Anil Kumar, N. V., Zucca, P., Varoni, E. M., Dini, L., Panzarini, E., Rajkovic, J., Fokou, P.V.T., Azzini, E., Peluso, I., Mishra, A.P., Nigam, M., El Rayess, Y., El Beyrouthy, M., Polito, L., Iriti, M., Martins N., Martorell, M., Docea, A.O., Setzer, W.N., Calina, D., Cho, W.C., Sharifi-Rad, J. (2020). Lifestyle, oxidative stress, and antioxidants: back and forth in the pathophysiology of chronic diseases. Frontiers in physiology, 11, 694. https://doi.org/10.3389/fphys.2020.00694 Silva-Costa-Gomes, T., Gallart, L., Valles, J., Trillo, L., Minguella, J., & Puig, M. M. (2005). Low-vs high-dose almitrine combined with nitric oxide to prevent hypoxia during open-chest one-lung ventilation. British journal of anaesthesia , 95 (3), 410-416. https://doi.org/10.1093/bja/aei194 Sinha, K.A. (1972). Colorimetric Assay of Catalase. Annals of Biochemistry , 47, 389–394. Soudani, N. A, AfefTroudi, A. L., HanenB. A. L.,Ibtissem, B.A.Tahia, B. B andNajiba, Z. (2011). Cardioprotective effects of selenium on chromium(VI)-induced toxicity infemalerats . Ecotoxicology and Environmental Safety, 74, 513–520. Tabassum, S., Gangarapu, K., Thumma, G., Manda, S., & Anreddy, R. N. R. (2014). Cardioprotective activity of,-Bis [5-methyl-2-oxo-1, 2-dihydro-3H-indol-3-ylidene] carbonohydrazide Derivative against Doxorubicin Induced Cardiotoxicity in Rats. Journal of Chemistry. 2014:1-7 https://doi.org/10.1155/2014/260672 Teraoka, K., Hirano, M., Yamaguchi, K and Yamashina, A. (2000). Progressive cardiac dysfunction in adriamycin-induced cardiomyopathy rats. European Journal of Heart Failure, 2 , 373 –378. Tran, N., Garcia, T., Aniqa, M., Ali, S., Ally, A., & Nauli, S. M. (2022). Endothelial Nitric Oxide Synthase (eNOS) and the Cardiovascular System: in Physiology and in Disease States. American journal of biomedical science & research , 15 (2), 153–177. Vandenberg, R.J., Ryan, R.M. Carland, J.E., Imlach, W.L., Macdonald, J.C. (2014). GlycineTransport Inhibitor for the treatment of pain. Trends in pharmaceutical Sciences, 35(8),423-430. https://doi.org/10.1016/j.tips.2014.05.006 Vulesevic, B., Lavoie, S. S., Neagoe, P. E., Dumas, E., Räkel, A., White, M., & Sirois, M. G. (2019). CRP induces NETosis in heart failure patients with or without diabetes. ImmunoHorizons , 3 (8), 378-388. Wagner, G.S., Roe, C.R.,Limbird, L. E., Rosati, R. A and Wallace, A. G. (2003). The importance of identification of the myocardial-specific isoenzyme of creatine phosphokinase (MB form) in the diagnosis of acute myocardial infarction. Circulation, 47 , 263-269. Wallin, B., Rosengren, B.,Shertzer, H. G and Camejo G (1993). Lipoprotein oxidation and measurement of TBARS formation in single microlitre plate; it's use for evaluation of antioxidants. Analytical Biochemistry , 208 , 10-15. Wu, B. B., Leung, K. T., & Poon, E. N. (2022). Mitochondrial-Targeted Therapy for Doxorubicin-Induced Cardiotoxicity. International journal of molecular sciences , 23 (3), 1912. https://doi.org/10.3390/ijms23031912 Wu, Y., Ding, Y., Ramprasath, T., & Zou, M. H. (2021). Oxidative stress, GTPCH1, and endothelial nitric oxide synthase uncoupling in hypertension. Antioxidants & redox signaling , 34 (9), 750-764. DOI: 10.1089/ars.2020.8112 Wuri, L., Arosh, J. A., Wu, J. Z., & Banu, S. K. (2022). Exposure to hexavalent chromium causes infertility by disrupting cytoskeletal machinery and mitochondrial function of the metaphase II oocytes in superovulated rats. Toxicology Reports , 9 , 219-229. https://doi.org/10.1016/j.toxrep.2022.02.002 Yang, F., Teves, S.S., Kemp, C.J., Henikoff,, S. (2014). Doxorubicin, DNA torsion, and chromatin dynamics. Biochim. Biophys. Acta. , 1845 , 84–89. https://doi.org/10.1016/j.bbcan.2013.12.002 Yokota, T., & Kinugawa, S. (2021). Premedication with pioglitazone prevents doxorubicin-induced left ventricular dysfunction in mice. BMC Pharmacology and Toxicology , 22, 27. https://doi.org/10.1186/s40360-021-00495-w Zhai, Q., Gong, X., Wang, C., Zhao, J., Zhang, H., Tian, F., & Chen, W. (2019). Food-borne patulin toxicity is related to gut barrier disruption and can be prevented by docosahexaenoic acid and probiotic supplementation. Food & function , 10 (3), 1330-1339. Zompatori, M., Ciccarese, F., & Fasano, L. (2014). Overview of current lung imaging in acute respiratory distress syndrome. European respiratory review , 23 (134), 519-530. Pokhrel, G. R., & Pokhre, G. (2022). The Effect of Chromium on Human-Health: A Review. BMC Journal of Scientific Research , 5 (1), 27-35. Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-2847266","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":194092613,"identity":"32687d49-69af-4125-9998-f23f5616c2bc","order_by":0,"name":"Onyedikachi,Uchechi Bliss","email":"data:image/png;base64,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","orcid":"https://orcid.org/0000-0003-4591-0318","institution":"michael Okpara University of Agriculture, Umudike.","correspondingAuthor":true,"submittingAuthor":false,"prefix":"","firstName":"Uchechi","middleName":"Bliss","lastName":"Onyedikachi","suffix":""},{"id":194092862,"identity":"0f000c02-3438-439a-8683-bc392e8a6c73","order_by":1,"name":"Egbuonu, Anthony Cemaluk Chinedum","email":"","orcid":"https://orcid.org/0000-0001-5974-415X","institution":"michael Okpara University of Agriculture, Umudike.","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Anthony","middleName":"Cemaluk Chinedum","lastName":"Egbuonu","suffix":""},{"id":194092863,"identity":"8f13f57d-cd57-4b05-b132-9fa18f0fc07f","order_by":2,"name":"Awah, Favour Matthew","email":"","orcid":"https://orcid.org/0000-0002-5259-3616","institution":"michael Okpara University of Agriculture, Umudike.","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Favour","middleName":"Matthew","lastName":"Awah","suffix":""},{"id":194092864,"identity":"33d4af7d-94e1-4763-89c5-d7dcd1891063","order_by":3,"name":"Ijioma, Solomon Nnah","email":"","orcid":"https://orcid.org/0000-0002-4239-5771","institution":"michael okpara university of agriculture,umudike","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Solomon","middleName":"Nnah","lastName":"Ijioma","suffix":""},{"id":194092865,"identity":"49b207e3-0941-40a4-9184-2f24ccc53e19","order_by":4,"name":"Kpobari W. Nkpaa","email":"","orcid":"https://orcid.org/0000-0003-0347-2348","institution":"university of portharcourt","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Kpobari","middleName":"W.","lastName":"Nkpaa","suffix":""}],"badges":[],"createdAt":"2023-04-22 03:35:17","currentVersionCode":1,"declarations":{"humanSubjects":false,"vertebrateSubjects":true,"conflictsOfInterestStatement":true,"humanSubjectEthicalGuidelines":false,"humanSubjectConsent":false,"humanSubjectClinicalTrial":false,"humanSubjectCaseReport":false,"vertebrateSubjectEthicalGuidelines":true,"coiExplicitlySet":false},"doi":"10.21203/rs.3.rs-2847266/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-2847266/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":36296860,"identity":"799d257b-246b-434d-94b9-78e73b7d4179","added_by":"auto","created_at":"2023-04-25 22:45:27","extension":"jpg","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":459978,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003e(A, B and C): Different doses of K\u003c/strong\u003e\u003csub\u003e\u003cstrong\u003e2\u003c/strong\u003e\u003c/sub\u003e\u003cstrong\u003eCr\u003c/strong\u003e\u003csub\u003e\u003cstrong\u003e2\u003c/strong\u003e\u003c/sub\u003e\u003cstrong\u003eO\u003c/strong\u003e\u003csub\u003e\u003cstrong\u003e7\u003c/strong\u003e\u003c/sub\u003e\u003cstrong\u003e and Dox impaired Antioxidant enzymes activities in the hearts of exposed Rats in the Treatment Phases (Phase 1, 2 and 3). \u003c/strong\u003e\u003cem\u003eValues are presented as Mean ± Standard error of mean. .s 'a' represents Superoxide dismutase activities; 'b' represents Catalase activities; 'c' represents Gluthathione peroxidase activities.\u003c/em\u003e\u003c/p\u003e","description":"","filename":"1.jpg","url":"https://assets-eu.researchsquare.com/files/rs-2847266/v1/27648d4c30a95a24d302d49a.jpg"},{"id":36295867,"identity":"cf944f44-ff7a-491d-b567-bfc8ed461183","added_by":"auto","created_at":"2023-04-25 22:37:27","extension":"jpg","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":133547,"visible":true,"origin":"","legend":"\u003cp\u003eMDA levels in Control Male Wistar rats and those treated with K\u003csub\u003e2\u003c/sub\u003eCr\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e7\u003c/sub\u003e and Dox. Values are means ± SE for six rats in each group. \u003cem\u003eValues are presented as Mean ± Standard error of mean.\u003c/em\u003e\u003c/p\u003e","description":"","filename":"2.jpg","url":"https://assets-eu.researchsquare.com/files/rs-2847266/v1/52bc83a77fd1798440e74697.jpg"},{"id":36295868,"identity":"5e761947-0e23-4a72-8736-0e3209a34c35","added_by":"auto","created_at":"2023-04-25 22:37:27","extension":"jpg","order_by":3,"title":"Figure 3","display":"","copyAsset":false,"role":"figure","size":476565,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003e(A, B and C):\u003c/strong\u003e Different doses of K\u003csub\u003e2\u003c/sub\u003eCr\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e7\u003c/sub\u003e and Dox induced increased activities of Aspartate transaminase (AST), Lactate dehydrogenase (LDH) and Creatinine Kinase (CK-MB) in the \u003cstrong\u003eTreatment Phases (Phase 1, 2 and 3)\u003c/strong\u003e. \u003cem\u003eValues are presented as Mean ± Standard error of mean.. 'a' represents AST; 'b' represents LDH; 'c' represents CK-MB.\u003c/em\u003e\u003cem\u003e\u003cstrong\u003e \u003c/strong\u003e\u003c/em\u003e\u003csub\u003e\u003cem\u003es.\u003c/em\u003e\u003c/sub\u003e\u003c/p\u003e","description":"","filename":"3.jpg","url":"https://assets-eu.researchsquare.com/files/rs-2847266/v1/52438c24cd2849232b3a87fc.jpg"},{"id":36295869,"identity":"e8b29a76-fe33-4fd0-939d-f21dd0a03c74","added_by":"auto","created_at":"2023-04-25 22:37:27","extension":"jpg","order_by":4,"title":"Figure 4","display":"","copyAsset":false,"role":"figure","size":191988,"visible":true,"origin":"","legend":"\u003cp\u003eDifferent doses of K\u003csub\u003e2\u003c/sub\u003eCr\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e7\u003c/sub\u003e and Doxorubicin increased Cardiac Troponin-I (CTnI) levels in all the treatment phases (First, Second and Third Phases). Values are presented as Mean ± Standard error of mean.\u003c/p\u003e","description":"","filename":"4.jpg","url":"https://assets-eu.researchsquare.com/files/rs-2847266/v1/86079e304e6a458c4cbd2e6e.jpg"},{"id":36297530,"identity":"89ea3442-e5ab-4c45-bd7d-87468792f931","added_by":"auto","created_at":"2023-04-25 22:53:27","extension":"jpg","order_by":5,"title":"Figure 5","display":"","copyAsset":false,"role":"figure","size":156898,"visible":true,"origin":"","legend":"\u003cp\u003eDifferent doses of K\u003csub\u003e2\u003c/sub\u003eCr\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e7\u003c/sub\u003e and Doxorubicin indicated increased C-Reactive Proteins (CRP) in all the treatment phases (First, Second and Third Phases). \u003cem\u003eValues are presented as Mean ± Standard error of mean.\u003c/em\u003e\u003c/p\u003e","description":"","filename":"5.jpg","url":"https://assets-eu.researchsquare.com/files/rs-2847266/v1/ca4456ce89b5a87f1899e3cf.jpg"},{"id":36295871,"identity":"20f71990-1348-4f4d-9643-6416fb10e6a9","added_by":"auto","created_at":"2023-04-25 22:37:27","extension":"jpg","order_by":6,"title":"Figure 6","display":"","copyAsset":false,"role":"figure","size":140095,"visible":true,"origin":"","legend":"\u003cp\u003eDifferent doses of K\u003csub\u003e2\u003c/sub\u003eCr\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e7\u003c/sub\u003e and Doxorubicin impaired Nitric Oxide (NO) levels in the heart of treated Rats in all phases (First, Second and Third Phases). \u003cem\u003eValues are presented as Mean ± Standard error of mean.\u003c/em\u003e\u003c/p\u003e","description":"","filename":"6.jpg","url":"https://assets-eu.researchsquare.com/files/rs-2847266/v1/61b6dfaacde96e350eb2fc8a.jpg"},{"id":36295875,"identity":"c841e318-f13f-4baf-a6fc-e4c13ccb63c1","added_by":"auto","created_at":"2023-04-25 22:37:28","extension":"jpg","order_by":7,"title":"Figure 7","display":"","copyAsset":false,"role":"figure","size":651565,"visible":true,"origin":"","legend":"\u003cp\u003eEffect of K\u003csub\u003e2\u003c/sub\u003eCr\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e7 \u003c/sub\u003eand Doxorubicin in phase 1 histopathological alteration in the hearts of Male Wistar Rats for 21 days (H \u0026amp; E X400, representative photomicrographs). (a) Control rats received an equal volume of normal drinking water orally for 21 consecutive days, (b) Rats were orally treated with 10 mg/kg body weight of K\u003csub\u003e2\u003c/sub\u003eCr\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e7\u003c/sub\u003e [Cr(VI)] compound for 21 consecutive days, (c) Rats were orally treated with 20 mg/kg body weight of K\u003csub\u003e2\u003c/sub\u003eCr\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e7\u003c/sub\u003e [Cr(VI)]\u0026nbsp; compound for 21 consecutive days, (d) Rats were orally treated with 30 mg/kg body weight of K\u003csub\u003e2\u003c/sub\u003eCr\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e7\u003c/sub\u003e [Cr(VI)]\u0026nbsp; compound for 21 consecutive days, (e)15 mg/kg body weight doxorubicin (2 days before sacrifice) administered intraperitoneally, (f)20 mg/kg body weight doxorubicin (2 days before sacrifice) administered intraperitoneally.\u003c/p\u003e","description":"","filename":"7.jpg","url":"https://assets-eu.researchsquare.com/files/rs-2847266/v1/27aa87109aa012f50383b58c.jpg"},{"id":36295874,"identity":"54eb7ba8-52b6-417b-a992-cd63665223c4","added_by":"auto","created_at":"2023-04-25 22:37:27","extension":"jpg","order_by":8,"title":"Figure 8","display":"","copyAsset":false,"role":"figure","size":735655,"visible":true,"origin":"","legend":"\u003cp\u003eEffect of K\u003csub\u003e2\u003c/sub\u003eCr\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e7 \u003c/sub\u003eand Doxorubicin in phase 2 on histopathological alteration in the hearts of Male Wistar Rats for 60 days (H \u0026amp; E X400, representative photomicrographs). (g) Control rats received an equal volume of normal drinking water orally for 60 consecutive days, (h) Rats were orally treated with 10 mg/kg body weight of K\u003csub\u003e2\u003c/sub\u003eCr\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e7\u003c/sub\u003e [Cr(VI)] compound for 60 consecutive days, (i) Rats were orally treated with 20 mg/kg body weight of K\u003csub\u003e2\u003c/sub\u003eCr\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e7\u003c/sub\u003e [Cr(VI)]\u0026nbsp; compound for 60 consecutive days, (j) Rats were orally treated with 30 mg/kg body weight of K\u003csub\u003e2\u003c/sub\u003eCr\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e7\u003c/sub\u003e [Cr(VI)]\u0026nbsp; compound for 60 consecutive days, (k)15 mg/kg body weight doxorubicin (2 days before sacrifice) administered intraperitoneally,(l)20 mg/kg body weight doxorubicin (2 days before sacrifice) administered intraperitoneally.\u003c/p\u003e","description":"","filename":"8.jpg","url":"https://assets-eu.researchsquare.com/files/rs-2847266/v1/56ab5de9c8ac6431ff0c7dc9.jpg"},{"id":36296861,"identity":"1026c7d3-e07e-403c-8f96-86d811fcb164","added_by":"auto","created_at":"2023-04-25 22:45:27","extension":"png","order_by":9,"title":"Figure 9","display":"","copyAsset":false,"role":"figure","size":2010520,"visible":true,"origin":"","legend":"\u003cp\u003eEffect of K\u003csub\u003e2\u003c/sub\u003eCr\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e7 \u003c/sub\u003eand Doxorubicin in phase 3 on histopathological alteration in the hearts of Male Wistar Rats (H \u0026amp; E X400 representative photomicrographs). (m) Control rats were fed with a standard pellet diet and received an equal volume of distilled water, (n) 0.01% of K\u003csub\u003e2\u003c/sub\u003eCr\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e7\u003c/sub\u003e [Cr(VI)] compound in feed, i.e. 10mg/kg of K\u003csub\u003e2\u003c/sub\u003eCr\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e7\u003c/sub\u003e [Cr(VI)]\u0026nbsp; compound per Kg Bodyweight in 100g of Rat feed for 60 days, (o) 0.02% of K\u003csub\u003e2\u003c/sub\u003eCr\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e7\u003c/sub\u003e [Cr(VI)] compound in feed, i.e. 20mg/kg of K\u003csub\u003e2\u003c/sub\u003eCr\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e7\u003c/sub\u003e [Cr(VI)]\u0026nbsp; compound per Kg Bodyweight in 100g of Rat feed for 60 days, (p) 0.03% of K\u003csub\u003e2\u003c/sub\u003eCr\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e7\u003c/sub\u003e [Cr(VI)] compound in feed, i.e. 30mg/kg of K\u003csub\u003e2\u003c/sub\u003eCr\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e7\u003c/sub\u003e [Cr(VI)] compound per Kg Bodyweight in 100g of Rat feed for 60 days, (q) 15 mg/kg body weight Dox (2 days before sacrifice) administered intraperitoneally, (r) 20 mg/kg body weight doxorubicin (2 days before sacrifice) administered intraperitoneally.\u003c/p\u003e","description":"","filename":"9.png","url":"https://assets-eu.researchsquare.com/files/rs-2847266/v1/53938b698af2fd14d41d3d13.png"},{"id":36297865,"identity":"94c9d018-2a26-4103-9440-f98e233e66a7","added_by":"auto","created_at":"2023-04-25 23:01:34","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":3407577,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-2847266/v1/0f186f1d-1597-4739-a9d3-c73f9c444879.pdf"}],"financialInterests":"","formattedTitle":"\u003cp\u003eComparative Evaluation of Vehicle, Dose, and Duration-related Oxidative, Cardiotoxic, Inflammatory and Histologic Responses of Chromium 6\u003csup\u003e+\u003c/sup\u003e and Doxorubicin in Rats’ Heart\u003c/p\u003e","fulltext":[{"header":"1.0 Introduction","content":"\u003cp\u003eChromium pollution is a severe threat to man and the entire ecosystem. Several researchers deduce the indiscriminate release of Cr [VI] compounds during industrial activities like photo production, chrome plating, paint making, welding, electroplating, and leather tanning as the major ways of Cr-pollution in the ecosystem (Garcia-nino \u003cem\u003eet al.\u003c/em\u003e,2015; Onyedikachi et al.,2018; Onyedikachi et al., 2019; Hashem et al., \u003cspan citationid=\"CR47\" class=\"CitationRef\"\u003e2020\u003c/span\u003e; Wuri et al., \u003cspan citationid=\"CR97\" class=\"CitationRef\"\u003e2022\u003c/span\u003e; Fagundes et al. \u003cspan citationid=\"CR30\" class=\"CitationRef\"\u003e2022\u003c/span\u003e. Firoozichahak et al.,2022). Cr (VI) toxicity has been implicated in various Organ toxicities like respiratory, gastrointestinal, hepatic, renal, neurological, and reproductive systems. It alters general development, causes increased ROS production which limits the activities of antioxidant enzymes, protein oxidation, and DNA damage (Bagchi et al., \u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e2002\u003c/span\u003e, Awasthi et al.,2018; Husain \u0026amp; Mahmood, \u003cspan citationid=\"CR51\" class=\"CitationRef\"\u003e2018\u003c/span\u003e; OEHHA, 2009; ATSDR, 2012; Remy \u0026amp; Clay, \u003cspan citationid=\"CR82\" class=\"CitationRef\"\u003e2014\u003c/span\u003e; Garcia-Nino \u003cem\u003eet al.\u003c/em\u003e, 2015; Onyedikachi et al., 2019; De Almeida et al., \u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e2021\u003c/span\u003e). The health effects of Cr, like other trace elements and chemicals of concern, may vary with the route of exposure, possibly, through inhalation, dermal contact, and ingestion of contaminated water and food crops grown in Cr-polluted soils (Onyedikachi et al., 2019; Das et al., \u003cspan citationid=\"CR24\" class=\"CitationRef\"\u003e2021\u003c/span\u003e; Prasad et al., 2021). Chromium (Cr) has varying oxidation states and solubility, the trivalent [Cr (III)] and hexavalent [Cr (VI)] forms (Carvalho et al., \u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e2014\u003c/span\u003e, Homa et al., \u003cspan citationid=\"CR50\" class=\"CitationRef\"\u003e2016\u003c/span\u003e, John, B.V., 2019). However, the Cr (VI) forms are more hazardous to health because they make up very strong oxidizing agents that get absorbed easily across the membranes through non-specific anion carriers (Pokhrel, G. R.\u0026amp; Pokhre, G. 2022)).\u003c/p\u003e \u003cp\u003eMany studies have revealed that cardiotoxicity may occur due to exposure to drugs, toxic metals, and other unknown causes (Guven et al.,2018). Cardiotoxicity results in myocardial and electrophysiology dysfunctions which affects the heart ability to pump blood efficiently resulting in various co-morbidities and deaths ((Tabassum et al., 2015; Mladěnka et al.,2018; Erbaş et al.,2022). Doxorubicin, an established cardiotoxic agent, is a broad-spectrum antitumor drug used to treat various cancers but could lead to cardiac failure and cardiomyopathies even after treatment cessation ((Hardaway, \u003cspan citationid=\"CR45\" class=\"CitationRef\"\u003e2019\u003c/span\u003e; Abdelatty et al.,2021; Morelli et al.,2022). The early damage occurs 1 to 3 days after drug administration, often resulting in apoptosis, necrosis, oxidative stress, which results in irreversible cardiotoxicity (Hardaway, \u003cspan citationid=\"CR45\" class=\"CitationRef\"\u003e2019\u003c/span\u003e). The molecular mechanisms of DOX-induced cardiotoxicity are unclear. Although, the suggestive possible mechanisms of action of DOX include DOX-mediated attack on the mitochondria, increase in reactive oxygen species, iron ferroptosis, disruption of calcium homeostasis, topoisomerase dysregulation and elevation in cardiac enzymes AST, LDH and CK\u0026ndash;MB, and Troponin (Fernandez-Chas et al., \u003cspan citationid=\"CR33\" class=\"CitationRef\"\u003e2018\u003c/span\u003e; Al-Malky et al.,2019; Morelli et al., \u003cspan citationid=\"CR66\" class=\"CitationRef\"\u003e2022\u003c/span\u003e).\u003c/p\u003e \u003cp\u003ePreviously, high levels of Cr\u003csup\u003e6+\u003c/sup\u003e were detected in soils and food crops grown around industrial areas in the South East of Nigeria (Garc\u0026iacute;a-Ni\u0026ntilde;o et al.,2015; Onyedikachi etal., 2019). This could indicate high level of Cr[VI] contamination and possible health risks. The dearth of information on the cardio toxic effect of Cr (VI) compounds and also, the growing concerns of possible cardio-related ailments observed among the residents and industrial workers in the areas (Garc\u0026iacute;a-Ni\u0026ntilde;o et al.,2015; Onyedikachi etal., 2019, OEHHA, 2009; NIOSH, \u003cspan citationid=\"CR69\" class=\"CitationRef\"\u003e2013\u003c/span\u003e; Das et al.,2015; Nur-E-Alam et al.,2020) warranted the present study aimed to evaluate and compare the vehicle, dose, and duration-based oxidative, cardiotoxic, inflammatory and histologic responses of administration of Cr (VI) (as potassium dichromate) and Dox in adult male Wistar rats\u0026rsquo; heart.\u003c/p\u003e"},{"header":"2.0 Material And Methods","content":"\u003cdiv id=\"Sec3\" class=\"Section2\"\u003e \u003ch2\u003e2.1 Chemicals and Drugs\u003c/h2\u003e \u003cp\u003ePotassium dichromate (K\u003csub\u003e2\u003c/sub\u003eCR\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e7\u003c/sub\u003e) was obtained from Sigma Chemical Co.(St. Loius, MO, USA). Doxorubicin and sterile water (Pfizer Drugs, USA) were purchased from Grace and Mercy Pharmacy, Umuahia, Nigeria. All other reagents were of analytical grade and were purchased from British drug houses (Poole, Dorset, UK).\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec4\" class=\"Section2\"\u003e \u003ch2\u003e2.2 Animal Husbandry\u003c/h2\u003e \u003cp\u003eA total of one hundred and eighty adult male Wistar albino rats (age:12week and body weight:120\u0026ndash;140 g) reared at the animal house, College of Veterinary Medicine, Michael Okpara University of Agriculture were used for this study. The animals were housed in well-ventilated plastic cages at the College of Natural Sciences, Michael Okpara University of Agriculture, Umudike, and subjected to a photoperiod of 12h light 12h dark cycle. They were allowed access to rat chow and drinking water ad libitum for 14 days. All investigations involving the experimental animals were strictly followed regarding the guidelines for the care and use of animals as defined by the National Institute of Health Committee on Care and Use of Laboratory Animals, Institute of Laboratory Animal Resources, USA (ILAR (\u003cspan citationid=\"CR52\" class=\"CitationRef\"\u003e1986\u003c/span\u003e).The experiment protocols were performed after the ethical approval was granted by the College of Natural Science, Research Ethics Committee (CREC/002/21), Michael Okpara University of Agriculture.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec5\" class=\"Section2\"\u003e \u003ch2\u003e2.3. \u003cb\u003eExperimental Design\u003c/b\u003e\u003c/h2\u003e \u003cp\u003eSixty (60) rats in three groups were used for each phase of treatment. The treatment phases include an acute exposure phase and two chronic exposure phases.\u003c/p\u003e \u003cp\u003eIn the I\u003csup\u003est\u003c/sup\u003e phase (acute phase exposure), group 1, control rats received an equal volume of normal drinking water orally for 21 consecutive days while groups 2, 3 and 4 rats were respectively orally treated (using Gavage) with 10 mg/kg, 20 mg/kg and 30 mg/kg body weight of K\u003csub\u003e2\u003c/sub\u003eCr\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e7\u003c/sub\u003e [Cr(VI)] compound for 21 consecutive days. Groups 5 and 6 rats respectively intraperitoneally received 15 mg/kg and 20 mg/kg body weight of doxorubicin (2 days before sacrifice).\u003c/p\u003e \u003cp\u003eThe protocol in the 2nd phase (chronic phase exposure) was as in the 1st phase but lasted for sixty (60) consecutive days.\u003c/p\u003e \u003cp\u003eIn the 3rd phase (chronic food supplementation phase), group 1, control rats were fed with a standard pellet diet and received an equal volume of distilled water. Group 2 rats received 0.01% of K\u003csub\u003e2\u003c/sub\u003eCr\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e7\u003c/sub\u003e [Cr(VI)] compound in feed i.e 10mg/kg of K\u003csub\u003e2\u003c/sub\u003eCr\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e7\u003c/sub\u003e [Cr(VI)] compound per kg body weight in 100g of Rat feed for 60 days. Group 3 rats received 0.02% of K\u003csub\u003e2\u003c/sub\u003eCr\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e7\u003c/sub\u003e [Cr(VI)] compound in feed i.e 20mg/kg of K\u003csub\u003e2\u003c/sub\u003eCr\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e7\u003c/sub\u003e [Cr(VI)] compound per kg body weight in 100g of Rat feed for 60 days. Group 4 rats received 0.03% of K\u003csub\u003e2\u003c/sub\u003eCr\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e7\u003c/sub\u003e [Cr(VI)] compound in feed i.e 30mg/kg of K\u003csub\u003e2\u003c/sub\u003eCr\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e7\u003c/sub\u003e [Cr(VI)] compound per kg body weight in 100g of Rat feed for 60 days. Group 5 and 6 rats respectively received intraperitoneal administration of 15 mg/kg and 20 mg/kg body weight of doxorubicin (2 days before sacrifice). The doses of K\u003csub\u003e2\u003c/sub\u003eCr\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e7\u003c/sub\u003e used in this study were based on the pilot study and as previously published (Navya et al.2018; Adjroud, \u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e2009\u003c/span\u003e) while doses of, and methods used for, Dox administration were based on earlier published reports (Radwan et al., \u003cspan citationid=\"CR80\" class=\"CitationRef\"\u003e2012\u003c/span\u003e; Biondo, 2016; Sandamali et al.,2019; Karabulut et al., 2021 and Furihata et al.,2021).\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec6\" class=\"Section2\"\u003e \u003ch2\u003e2.4 Preparation of heart samples\u003c/h2\u003e \u003cp\u003eAll analyses, including biochemical and histopathology assessment of heart tissue carried out in the first phase, were repeated in the second and third phases. On the 22nd and 61st day, i.e., after overnight fasting. Ketamine injection was administered intraperitoneally to anaesthetize the animals, followed by prompt excision of the respective rats\u0026rsquo; heart tissues. Part of the heart was rinsed in normal saline. One gram was weighed, sliced, and ground with laboratory mortar and pestle in a 5ml phosphate buffer solution. The resulting solution was centrifuged at 2200rpm for 25minutes in a cold centrifuge at 4\u003csup\u003e0\u003c/sup\u003ec. The supernatant (homogenate) was collected, labelled, and preserved in the freezer until analysis. The heart homogenates were used to assess CK-MB, CRP, AST, LDH, and Trop. Also, part of the heart was excised and fixed in 10% buffered formalin for a histopathology examination.\u003c/p\u003e \u003cdiv id=\"Sec7\" class=\"Section3\"\u003e \u003ch2\u003e2.4.1 Body Weight and Relative Organ Weight\u003c/h2\u003e \u003cp\u003eThe body weight of each rat in the groups was weighed at the beginning of the study and on the day of sacrifice. The excised organs (heart) were weighed during the sacrifice to calculate the relative organ weight(using the formula below) and observed for gross lesions.\u003cdiv id=\"Equa\" class=\"Equation\"\u003e\u003cdiv format=\"TEX\" class=\"mathdisplay\" id=\"FileID_Equa\" name=\"EquationSource\"\u003e\n$$Relative organ weight =\\frac{Organ weight \\left(g\\right) of animal on sacrifice day \\left(g\\right) }{Body weight \\left(g\\right) of animal on sacricice day } X 100$$\u003c/div\u003e\u003c/div\u003e\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv id=\"Sec8\" class=\"Section2\"\u003e \u003ch2\u003e2.5 Biochemistry Assay\u003c/h2\u003e \u003cp\u003eSOD activity was assayed by the method of Arthur and Boyne (\u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e1985\u003c/span\u003e). GP\u003csub\u003eX\u003c/sub\u003e assay was carried out according to the method of Paglia and Valentine (1967). The activity of Catalase was assayed by the method of Sinha (\u003cspan citationid=\"CR86\" class=\"CitationRef\"\u003e1972\u003c/span\u003e). Lipid peroxidation product (MDA) was assayed according to the method described by Wallin (1993). LDH assay was carried out according to the method used by Jung (2000). CK-MB assay was carried out according to the method of Henry (1974). AST assay was according to the method of Reitman and Frankel (\u003cspan citationid=\"CR81\" class=\"CitationRef\"\u003e1975\u003c/span\u003e). NO assay was also carried out according to the method described by Dessy and Ferron (\u003cspan citationid=\"CR26\" class=\"CitationRef\"\u003e2004\u003c/span\u003e). Spectrophotometric reading was assessed using D3900 UV-VIS Spectrophotometer (Hach TechnologiesLoveland USA.)\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec9\" class=\"Section2\"\u003e \u003ch2\u003e2.6 Immuno Assays\u003c/h2\u003e \u003cp\u003eThe Troponin test (CTnI) was carried out according to the method of Melanson (2007). C-reactive proteins (CRP) were analyzed using the method of Anderson and Mccarthy (\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e1950\u003c/span\u003e) as determined using commercially available ELISA kits following the procedure described in the manual.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec10\" class=\"Section2\"\u003e \u003ch2\u003e2.7 Preparation of slides for histopathological evaluation\u003c/h2\u003e \u003cp\u003eThe hearts of the rats were isolated immediately after sacrifice, washed with cold phosphate-buffered saline (pH\u0026thinsp;=\u0026thinsp;7.4) and fixed in 10% buffered formalin. Tissues were embedded in paraffin, and 5m serial sections of the heart were taken. These sections were stained with Hematoxylin and Eosin (H\u0026amp;E). Changes in the histopathology were observed under a light microscope (Olympus BX10, Tokyo, Japan), and images were taken using a digital camera. The individual performing the evaluation was blinded to the treatment given to the respective groups. Tissue sections of the heart were collected for histopathological studies. Prior to the commencement of tissue preparation, the heart samples were fixed in formalin (10% buffered) after washing with cold phosphate-buffered saline (7.4). The tissues were prepared by trimming and dehydrating in 70%, 80%, 90%, and absolute alcohol, clearing in 3 grades of xylene, and solidifying the tissues in molten wax. On solidifying, the tissue-containing wax blocks were cut into 5\u0026micro;m thick sections with a rotary microtome, floated in a water bath, and incubated at 60\u003csup\u003e˚\u003c/sup\u003eC for 30 minutes. The 5\u0026micro;m thick sectioned tissues were cleared in 3 grades of xylene and rehydrated in 3 grades of alcohol (90%, 80%, and 70%). The sections were then stained with Hematoxylin for 15 minutes. Blueing was done with ammonium chloride, and differentiation was done with 1% acid alcohol before counterstaining with Eosin. Permanent mounts were made on degreased glass slides using a mountant, DPX. The prepared slides were examined with a Motic\u0026trade; compound light microscope using x4, x10, and x40 objective lenses. The photomicrographs were taken using a Motic\u0026trade; 5.0 megapixels microscope camera at x400 magnifications.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec11\" class=\"Section2\"\u003e \u003ch2\u003e2.8 Statistical Analysis\u003c/h2\u003e \u003cp\u003eThe least significant difference (LSD) was used to compare differences in each sample within treatments. Data were reported as mean\u0026thinsp;\u0026plusmn;\u0026thinsp;Standard Error (SE). One-way analysis of variance (ANOVA) was also used to determine significant differences between groups, considering a level of significance of less than or equal to (\u003cem\u003eP\u003c/em\u003e\u0026thinsp;\u0026lt;\u0026thinsp;0.05) by using SPSS. The significant difference was assessed using Duncan at (\u003cem\u003eP\u003c/em\u003e\u0026thinsp;\u0026lt;\u0026thinsp;0.05).\u003c/p\u003e \u003c/div\u003e"},{"header":"3.0 Result","content":"\u003cdiv id=\"Sec13\" class=\"Section2\"\u003e\n \u003cp\u003e\u003cstrong\u003e3.1 Absolute and Relative Heart Weight\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003eThe absolute and relative heart weights of rats treated orally (by administration with Gavage) with K\u003csub\u003e2\u003c/sub\u003eCr\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e7\u003c/sub\u003e for 21 days are presented, respectively, in \u003cspan class=\"InternalRef\"\u003eAppendix\u003c/span\u003e 1. The experimental rats\u0026apos; absolute and relative heart weights indicated no significant difference compared to the Control (p\u0026thinsp;\u0026lt;\u0026thinsp;0.05). However, a slight increase in the absolute and relative heart weight of groups treated with K\u003csub\u003e2\u003c/sub\u003eCr\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e7\u003c/sub\u003e for 60days was observed compared to the Doxorubicin and Normal (Control) groups for all treatment routes.\u003c/p\u003e\n \u003cp\u003e\u003cstrong\u003e3.2 Different doses of K\u003c/strong\u003e \u003csub\u003e\u0026nbsp;\u003cstrong\u003e2\u003c/strong\u003e\u0026nbsp;\u003c/sub\u003e \u003cstrong\u003eCr\u003c/strong\u003e \u003csub\u003e\u0026nbsp;\u003cstrong\u003e2\u003c/strong\u003e\u0026nbsp;\u003c/sub\u003e \u003cstrong\u003eO\u003c/strong\u003e \u003csub\u003e\u0026nbsp;\u003cstrong\u003e7\u003c/strong\u003e\u0026nbsp;\u003c/sub\u003e \u003cstrong\u003eand Doxorubicin impaired Antioxidant enzymes following acute and chronic exposure to Rats in the Treatment Phases (Phase 1, 2 and 3).\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003eResults presented in Fig.\u0026nbsp;\u003cspan class=\"InternalRef\"\u003e1\u003c/span\u003e (A, B and C) show that rats exposed to K\u003csub\u003e2\u003c/sub\u003eCr\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e7\u003c/sub\u003e and Dox respectively elicited a significant (p\u0026thinsp;\u0026lt;\u0026thinsp;0.05) decrease in GPx, CAT, and SOD activities in the treatment phases relative to the control (Group 1).\u003c/p\u003e\n \u003cp\u003eIn phase 1,The SOD activities decreased by 0.89%,10.62%, 24.78% K\u003csub\u003e2\u003c/sub\u003eCr\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e7\u003c/sub\u003e treated Rats, CAT activities also decreased by 30.86%,42.23% and 48.03% in K\u003csub\u003e2\u003c/sub\u003eCr\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e7\u003c/sub\u003e treated rats, likewise, GPx activities decreased by 12.96%, 21.96% and 34.01% in rats treated with 10mg/kg, 20mg and 30mg/kg K\u003csub\u003e2\u003c/sub\u003eCr\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e7\u003c/sub\u003e respectively, relative to the normal control animals. Similarly, animals treated with 15mg/kg and 20mg/kg Dox in groups 5 and 6 showed decreased GPx, CAT, and SOD activities. The percentage decreases in the enzyme activities for groups 5 and 6 relative to the control group were 2.65% and 4.24%(SOD), 0.23% and 18.33%(CAT), and 34.4% and 12.55%(GPx).\u003c/p\u003e\n \u003cp\u003eIn the Second phase, the SOD activities decreased by 20%, 22.5%, 39.17% in K\u003csub\u003e2\u003c/sub\u003eCr\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e7\u003c/sub\u003e treated rats, CAT activities also decreased by 19.34%, 30.82% and 45.62% in K\u003csub\u003e2\u003c/sub\u003eCr\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e7\u003c/sub\u003e treated rats. Likewise, GPx activities decreased by 2.70%, 21.95% and 30.62% in Rats treated with 10mg/kg, 20mg and 30mg/kg K\u003csub\u003e2\u003c/sub\u003eCr\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e7\u003c/sub\u003e respectively relative to the Normal control animals. Similarly, animals that received 15mg/kg and 20mg/kg Dox) in Groups 5 and 6 showed decreased GPx, CAT, and SOD activities by 10.38% and 14.17%, 1.81%, and 9.37%, 5.42%, and 8.40% respectively compared to the enzyme activities recorded for the Normal Control(Group 1).\u003c/p\u003e\n \u003cp\u003eIn the Third Phase, the SOD activities decreased by 2.90%, 11.63%, and 22.67% K\u003csub\u003e2\u003c/sub\u003eCr\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e7\u003c/sub\u003e in treated Rats. CAT activities also decreased by 4.04%, 40%, and 45% in K\u003csub\u003e2\u003c/sub\u003eCr\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e7\u003c/sub\u003e treated rats. Likewise, GPx activities decreased by 26.92%, 35.49% and 38.11% in Rats treated with 10mg/kg, 20mg and 30mg/kg K\u003csub\u003e2\u003c/sub\u003eCr\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e7\u003c/sub\u003e respectively relative to the normal control animals.\u003c/p\u003e\n \u003cp\u003eSimilarly, animals treated with 15mg/kg and 20mg/kg Doxorubicin (Dox) in Groups 5 and 6 decreased the enzyme activities by 30.81% and 32.56% (SOD), 1.21% and 3.24%(CAT), and 27.27% and 27.47% (GPx) compared to the normal Control(Group 1).\u003c/p\u003e\n \u003cp\u003e3.3 \u003cstrong\u003eTreating rats with different doses of K\u003c/strong\u003e\u003csub\u003e\u003cstrong\u003e2\u003c/strong\u003e\u003c/sub\u003e\u003cstrong\u003eCr\u003c/strong\u003e\u003csub\u003e\u003cstrong\u003e2\u003c/strong\u003e\u003c/sub\u003e\u003cstrong\u003eO\u003c/strong\u003e\u003csub\u003e\u003cstrong\u003e7\u003c/strong\u003e\u003c/sub\u003e \u003cstrong\u003eand Dox induced Oxidative Stress in all the treatment phases (First, Second and Third Phases).\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003eThe results presented in Fig.\u0026nbsp;\u003cspan class=\"InternalRef\"\u003e2\u003c/span\u003e shows the level of MDA investigated in the hearts of the Control, K\u003csub\u003e2\u003c/sub\u003eCr\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e7,\u003c/sub\u003e and Dox treated Rats. The Rats that received both K\u003csub\u003e2\u003c/sub\u003eCr\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e7\u003c/sub\u003e and Dox showed a significant increase in MDA levels following the First, Second and Third treatment Phases when compared to the Normal Control, the percentage increase in MDA levels for the Rats treated with 10mg/kg, 20mg/kg, and 30mg/kg K2Cr2O7 was 16.67%, respectively, 63.33%, 90.00%, respectively, in the first phase.\u003c/p\u003e\n \u003cp\u003eIn the second phase, the MDA levels increased significantly by 46%, 151.47%, and 368.38% compared to the levels observed in the Control. Similarly, the percentage increases observed compared to Control for the third treatment phases were 18.55%, 23.39% and 33.87% for 10mg/kg, 20mg/kg, and 30mg/kg K\u003csub\u003e2\u003c/sub\u003eCr\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e7\u003c/sub\u003e respectively.\u003c/p\u003e\n \u003cp\u003eIn the Dox groups (5 and 6), the Rats treated indicated similar spike increases (p\u0026thinsp;\u0026lt;\u0026thinsp;0.05) in the levels of MDA compared to the levels observed in the Control. The percentage increases were 3.33% and 40% (First Phase), 2.21% and 27.94%(Second phase), and 26.61% and 28.23% (Third Phase) for Rats treated with 15mg/kg and 20mg/kg Dox treated groups respectively.\u003c/p\u003e\n \u003cp\u003e3.4 \u003cstrong\u003eRats treated with different doses of K\u003c/strong\u003e\u003csub\u003e\u003cstrong\u003e2\u003c/strong\u003e\u003c/sub\u003e\u003cstrong\u003eCr\u003c/strong\u003e\u003csub\u003e\u003cstrong\u003e2\u003c/strong\u003e\u003c/sub\u003e\u003cstrong\u003eO\u003c/strong\u003e\u003csub\u003e\u003cstrong\u003e7\u003c/strong\u003e\u003c/sub\u003e \u003cstrong\u003eand Dox showed increased Cardiac markers (AST, LDH, and CK-MB) activities in the first treatment phase.\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003eResults presented in Fig.\u0026nbsp;\u003cspan class=\"InternalRef\"\u003e3\u003c/span\u003e (A, B and C) show that rats exposed to K\u003csub\u003e2\u003c/sub\u003eCr\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e7\u003c/sub\u003e and Dox respectively elicited a significant (p\u0026thinsp;\u0026lt;\u0026thinsp;0.05) increase in AST, LDH, and CK-MB activities in the treatment phases relative to the control (Group 1).\u003c/p\u003e\n \u003cp\u003e\u003cstrong\u003eIn the phase 1\u003c/strong\u003e, AST results indicated 22.53%, 37.56%, and 64.39% increases in enzyme activities. LDH activities also increased by 55.24%, 73.82%, and 116.10%. Also, CK-MB activities followed the increasing trend by 16.46%, 45.60%, and 87.63% for Rats treated with 10mg/kg, 20mg/kg, and 30mg/kg K\u003csub\u003e2\u003c/sub\u003eCr\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e7,\u003c/sub\u003e respectively, when compared to the Control group. Similarly, the rats treated with 15mg/kg and 20mg/kg Dox in groups 5 and 6 indicated increased AST, LDH, and CK-MB activities. The percentage increases in activities for groups 5 and 6 compared to the control group were 2.65% and 4.24% (AST), 0.23% and 18.33%(LDH), and 34.4% and 12.55%(CK-MB).\u003c/p\u003e\n \u003cp\u003eIn the second phase, the AST results indicated 30.76%, 38.73%, and 93.56% increases in enzyme activities. LDH activities also increased by 34.37%, 47.17%, and 70.25%. Also, CK-MB activities followed the increasing trend by 33.15%, 58.80%, and 101.12% for Rats treated with 10mg/kg, 20mg/kg, and 30mg/kg K\u003csub\u003e2\u003c/sub\u003eCr\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e7,\u003c/sub\u003e respectively, when compared to the Normal group. Likewise, the rats treated with 15mg/kg and 20mg/kg Doxorubicin(Dox) in groups 5 and 6, respectively, indicated increases in AST, LDH, and CK-MB activities. The percentage increases in activities for groups 5 and 6 compared to the control group were 5.28% and 4.56%(AST), 38.33% and 56.43%(LDH), and 9.71% and 18.13%(CK-MB).\u003c/p\u003e\n \u003cp\u003eIn the third phase, the AST results indicated 12.35%, 25.20%, and 33.89% increases in enzyme activities. LDH activities also increased by 3.56%, 10.32%, and 13.48%. Also, CK-MB activities followed the increasing trend by 8.55%, 25.48%, and 101.12% for Rats treated with 10mg/kg, 20mg/kg, and 30mg/kg K\u003csub\u003e2\u003c/sub\u003eCr\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e7,\u003c/sub\u003e respectively, when compared to the Normal group.\u003c/p\u003e\n \u003cp\u003eSimilarly, the rats treated with 15mg/kg and 20mg/kg Doxorubicin (Dox) in groups 5 and 6, respectively, showed elevated levels of AST, LDH, and CK-MB activities. The percentage increases in activities for groups 5 and 6 compared to the control group were 5.28% and 4.56% (AST), 38.33% and 56.43%(LDH), and 9.71% and 18.13%(CK-MB).\u003c/p\u003e\n \u003cp\u003e3.5 \u003cstrong\u003eRats treated with different doses of K\u003c/strong\u003e\u003csub\u003e\u003cstrong\u003e2\u003c/strong\u003e\u003c/sub\u003e\u003cstrong\u003eCr\u003c/strong\u003e\u003csub\u003e\u003cstrong\u003e2\u003c/strong\u003e\u003c/sub\u003e\u003cstrong\u003eO\u003c/strong\u003e\u003csub\u003e\u003cstrong\u003e7\u003c/strong\u003e\u003c/sub\u003e \u003cstrong\u003eand Dox increased Cardiac Troponin-I(CTnI) levels in all the treatment phases(First, Second and Third Phases).\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003eThe results in Fig.\u0026nbsp;\u003cspan class=\"InternalRef\"\u003e4\u003c/span\u003e shows the levels of CTnI investigated in the hearts of the Control, K\u003csub\u003e2\u003c/sub\u003eCr\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e7,\u003c/sub\u003e and Dox\u003csub\u003e\u0026minus;\u003c/sub\u003etreated Rats with a significant increase in CTnI levels in all the treatment Phases. The percentage increase in CTnI levels for the Rats treated with 10mg/kg, 20mg/kg, and 30mg/kg K\u003csub\u003e2\u003c/sub\u003eCr\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e7\u003c/sub\u003e compared to the Normal Control was 29.18%, 35.01%, 38.91% for the first phases.\u003c/p\u003e\n \u003cp\u003eIn the second phase, the CTnI levels increased significantly by 63.76%, 65.07%, and 71.62% compared to the levels observed in the Control. Also, the percentage increases observed compared to Control for the third treatment phase were 2.28%, 3.33% and 9.52% for 10mg/kg, 20mg/kg, and 30mg/kg K\u003csub\u003e2\u003c/sub\u003eCr\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e7\u003c/sub\u003e respectively.\u003c/p\u003e\n \u003cp\u003eIn the Dox groups(5 and 6), the Rats treated indicated similar increases(p\u0026thinsp;\u0026lt;\u0026thinsp;0.05) in the levels of CTnI compared to the levels observed in the Control. The percentage increases were 4.67% and 15.57% (First Phase), 20.09% and 10.48%(Second phase), and 3.81% and 4.77% (Third phase) for Rats treated with 15mg/kg and 20mg/kg Dox treated groups respectively.\u003c/p\u003e\n \u003cp\u003e\u003cstrong\u003e3.6 Rats treated with different doses of K\u003c/strong\u003e \u003csub\u003e\u0026nbsp;\u003cstrong\u003e2\u003c/strong\u003e\u0026nbsp;\u003c/sub\u003e \u003cstrong\u003eCr\u003c/strong\u003e \u003csub\u003e\u0026nbsp;\u003cstrong\u003e2\u003c/strong\u003e\u0026nbsp;\u003c/sub\u003e \u003cstrong\u003eO\u003c/strong\u003e \u003csub\u003e\u0026nbsp;\u003cstrong\u003e7\u003c/strong\u003e\u0026nbsp;\u003c/sub\u003e \u003cstrong\u003eand Dox indicated increased C-Reactive Proteins (CRP) in all the treatment phases (First, Second and Third Phases).\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003eResults presented in Fig.\u0026nbsp;\u003cspan class=\"InternalRef\"\u003e5\u003c/span\u003e shows spikes in C- Reactive Protein levels compared to Control, K\u003csub\u003e2\u003c/sub\u003eCr\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e7,\u003c/sub\u003e and Dox treated Rats. The percentage increase in CRP levels for the Rats treated with 10mg/kg, 20mg/kg and 30mg/kg K\u003csub\u003e2\u003c/sub\u003eCr\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e7\u003c/sub\u003e compared to the normal Control were 35.62%, 45.21%, 82.19% for the first phases. In the second phase, the CRP levels increased significantly by 113%, 229%, and 300% compared to the observed control values.\u003c/p\u003e\n \u003cp\u003eAlso, the percentage increases observed compared to Control for the third treatment phases were 2.56%, 9.29% and 18.27% for 10mg/kg, 20mg/kg, and 30mg/kg K\u003csub\u003e2\u003c/sub\u003eCr\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e7\u003c/sub\u003e respectively. In the Dox groups(5 and 6), the Rats treated indicated similar spike increases(p\u0026thinsp;\u0026lt;\u0026thinsp;0.05) in the levels of CRP compared to the levels observed in the Control. The percentage increases were 23.28% and 23.29% (First Phase), 38% and 114%(Second phase), and 2.56% and 7.05% (Third phase) for Rats treated with 15mg/kg and 20mg/kg Dox treated groups respectively.\u003c/p\u003e\n \u003cp\u003e3.7 \u003cstrong\u003eDifferent doses of K\u003c/strong\u003e\u003csub\u003e\u003cstrong\u003e2\u003c/strong\u003e\u003c/sub\u003e\u003cstrong\u003eCr\u003c/strong\u003e\u003csub\u003e\u003cstrong\u003e2\u003c/strong\u003e\u003c/sub\u003e\u003cstrong\u003eO\u003c/strong\u003e\u003csub\u003e\u003cstrong\u003e7\u003c/strong\u003e\u003c/sub\u003e \u003cstrong\u003eand Dox inhibited Nitric Oxide levels in the heart of treated Rats in all phases(First, Second and Third Phases).\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003e\u003cstrong\u003eResults presented on\u003c/strong\u003e Fig.\u0026nbsp;\u003cspan class=\"InternalRef\"\u003e6\u003c/span\u003e shows decreases in the levels of NO availability in the hearts of K\u003csub\u003e2\u003c/sub\u003eCr\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e7\u003c/sub\u003e and Dox-treated rats compared to the Control. The percentage decrease in NO levels for the Rats treated with 10mg/kg, 20mg/kg, and 30mg/kg K\u003csub\u003e2\u003c/sub\u003eCr\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e7\u003c/sub\u003e compared to the normal Control were 4.65%, 18.61%, 27.91% for the first phase. Conversely, in the second phase, NO indicated an increase of 31.7%, 41.7%, and 76.8% compared to the Control.\u003c/p\u003e\n \u003cp\u003eAlso, percentage increases were observed compared to control for the third treatment phases were as follows: 385%, 885% and 1200% for 10mg/kg, 20mg/kg, and 30mg/kg K\u003csub\u003e2\u003c/sub\u003eCr\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e7,\u003c/sub\u003e respectively. The NO levels in Dox groups (5 and 6) in the first phase indicated a slight decrease compared to control levels. In contrast, a significant increase (p\u0026thinsp;\u0026lt;\u0026thinsp;0.05) was observed in the levels of NO in the second and third phases compared to the Control. The percentage decreases were 2.31% and 4.65% (First Phase), while the percentage increase was 19.5% and 1.22% (Second phase), and 750% and 1115% (Third Phase) for Rats treated with 15mg/kg and 20mg/kg Dox treated groups respectively.\u003c/p\u003e\n \u003cp\u003e3.8: The effect of administering K\u003csub\u003e2\u003c/sub\u003eCr\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e7\u003c/sub\u003e and Doxorubicin intraperitoneal injection on the myocardial histoarchitecture of animals treated in the first phase (H\u0026amp;E X400) representative photomicrographs followed by light microscopy are indicated as follows:\u003c/p\u003e\n \u003cp\u003e\u003cstrong\u003eHistopathology result\u003c/strong\u003e shows Alphabeths a-f representing various photomicrographs of the treatment groups in phase one (21 days). (a) depicts Control rats that received an equal volume of normal drinking water orally for 21 consecutive days, (b) Rats that received oral administration of 10 mg/kg body weight of K\u003csub\u003e2\u003c/sub\u003eCr\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e7\u003c/sub\u003e [Cr(VI)] compound for 21 consecutive days, (c) Rats that received oral administration of 20 mg/kg body weight of K\u003csub\u003e2\u003c/sub\u003eCr\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e7\u003c/sub\u003e [Cr(VI)] compound for 21 consecutive days, (d) Rats that received oral administration of 30 mg/kg body weight of K\u003csub\u003e2\u003c/sub\u003eCr\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e7\u003c/sub\u003e [Cr(VI)] compound for 21 consecutive days, (e)15 mg/kg body weight doxorubicin (2 days prior to sacrifice) administered intraperitoneally,(f)20 mg/kg body weight doxorubicin (2 days prior to sacrifice) administered intraperitoneally.\u003c/p\u003e\n \u003cp\u003e3.9 Effect of K\u003csub\u003e2\u003c/sub\u003eCr\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e7\u003c/sub\u003e and Doxorubicin in phase 2 histopthology results H and E X400, representative photomicrographs followed by light microscopy are indicated as follows:\u003c/p\u003e\n \u003cp\u003e\u003cstrong\u003eFig\u003c/strong\u003e 8 shows Alphabeths g-l representing various photomicrographs of the treatment groups in phase one(60 days). (g) Control rats that received an equal volume of normal drinking water orally for 60 consecutive days, (h) rats that received oral administration of 10 mg/kg body weight of K\u003csub\u003e2\u003c/sub\u003eCr\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e7\u003c/sub\u003e [Cr(VI)] compound for 60 consecutive days, (i) Rats that received oral administration of 20 mg/kg body weight of K\u003csub\u003e2\u003c/sub\u003eCr\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e7\u003c/sub\u003e [Cr(VI)]\u0026nbsp; compound for 60 consecutive days, (j) Rats that received oral administration of 30 mg/kg body weight of K\u003csub\u003e2\u003c/sub\u003eCr\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e7\u003c/sub\u003e [Cr(VI)]\u0026nbsp; compound for 60 consecutive days, (k) Rats given 15 mg/kg body weight doxorubicin (2 days prior to sacrifice) administered intraperitoneally,(l) rats given 20 mg/kg body weight doxorubicin (2 days prior to sacrifice) administered intraperitoneally.\u003c/p\u003e\n \u003cp\u003e3.10: Effect of K\u003csub\u003e2\u003c/sub\u003eCr\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e7\u003c/sub\u003e and Doxorubicin in phase 3 on the myocardial histoarchitecture of animals treated in the Third phase using the H\u0026amp;E staining E X400, representative photomicrographs followed by light microscopy are indicated as follows:\u003c/p\u003e\n \u003cp\u003eThe effect of treatment groups was represented using Alphabeths m-r on Fig.\u0026nbsp;9 shows m Control rats fed a standard pellet diet and received an equal volume of distilled water, n shows Rats given 0.01% of K\u003csub\u003e2\u003c/sub\u003eCr\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e7\u003c/sub\u003e [Cr(VI)] compound in feed, i.e., 10mg/kg of K\u003csub\u003e2\u003c/sub\u003eCr\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e7\u003c/sub\u003e [Cr(VI)] compound per Kg Bodyweight in 100g of Rat feed for 60 days, o shows Rats given 0.02% of K\u003csub\u003e2\u003c/sub\u003eCr\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e7\u003c/sub\u003e [Cr(VI)] compound in feed, i.e., 20mg/kg of K\u003csub\u003e2\u003c/sub\u003eCr\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e7\u003c/sub\u003e [Cr(VI)] compound per Kg Bodyweight in 100g of Rat feed for 60 days, p shows Rats given 0.03% of K\u003csub\u003e2\u003c/sub\u003eCr\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e7\u003c/sub\u003e [Cr(VI)] compound in feed, i.e., 30mg/kg of K\u003csub\u003e2\u003c/sub\u003eCr\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e7\u003c/sub\u003e [Cr(VI)] compound per kg Bodyweight in 100g of Rat feed for 60 days, q shows Rats given 15 mg/kg body weight Dox (2 days prior to sacrifice) administered intraperitoneally, r shows Rats given 20 mg/kg body weight doxorubicin (2 days prior to sacrifice) administered intraperitoneally.\u003c/p\u003e\n\u003c/div\u003e"},{"header":"4.0 Discussion","content":"\u003cp\u003eMany research data indicate that environmental exposure to Toxic metals is implicated in the severe pathogenesis of chronic diseases. In this present study, there was no mortality during the treatment phases. The rats also showed increased final body weights across groups, as seen in Tables \u003cspan class=\"InternalRef\"\u003e1\u003c/span\u003e. However, we observed a statistically marked increase in body weight of the control groups compared to those that received K\u003csub\u003e2\u003c/sub\u003eCr\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e7\u003c/sub\u003e and Dox. There was also a significant difference in the relative heart weight of rats fed K\u003csub\u003e2\u003c/sub\u003eCr\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e7\u003c/sub\u003e compared to the absolute heart weight of the Control and Dox-treated rats. It was also noted that as the concentration of K\u003csub\u003e2\u003c/sub\u003eCr\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e7\u003c/sub\u003e administered increased, reduced relative heart weight was observed in the experimental Rats. K\u003csub\u003e2\u003c/sub\u003eCr\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e7\u003c/sub\u003e intoxication may have been responsible for the rats\u0026apos; observed relative heart weight reduction. This finding agrees with (Soudani et al., \u003cspan class=\"CitationRef\"\u003e2011\u003c/span\u003e), where severe toxicity to brush border enzymes was observed by K\u003csub\u003e2\u003c/sub\u003eCr\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e7\u003c/sub\u003e intoxication. Likewise, (Hayyan et al., \u003cspan class=\"CitationRef\"\u003e2016\u003c/span\u003e) and (Wuri et al., \u003cspan class=\"CitationRef\"\u003e2022\u003c/span\u003e) have also buttressed K\u003csub\u003e2\u003c/sub\u003eCr\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e7\u003c/sub\u003e toxicity in kidneys and oocytes of exposed rats suggesting that oxidative damage may be responsible for the reduced relative organ weight.\u003c/p\u003e\n\u003cdiv class=\"gridtable\"\u003e\n \u003ctable id=\"Tab1\" border=\"1\"\u003e\n \u003ccaption\u003e\n \u003cdiv class=\"CaptionNumber\"\u003eTable 1\u003c/div\u003e\n \u003cdiv class=\"CaptionContent\"\u003e\n \u003cp\u003eEffect of K\u003csub\u003e2\u003c/sub\u003eCr\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e7\u003c/sub\u003e and Doxorubicin on the body weight, absolute and relative heart weights of rats (g).\u003c/p\u003e\n \u003c/div\u003e\n \u003c/caption\u003e\n \u003cthead\u003e\n \u003ctr\u003e\n \u003cth align=\"left\"\u003e\u0026nbsp;\u003c/th\u003e\n \u003cth align=\"left\"\u003e\u0026nbsp;\u003c/th\u003e\n \u003cth colspan=\"2\" align=\"left\"\u003e\n \u003cp\u003eHeart Weight\u003c/p\u003e\n \u003c/th\u003e\n \u003cth colspan=\"2\" align=\"left\"\u003e\n \u003cp\u003eBody Weight\u003c/p\u003e\n \u003c/th\u003e\n \u003c/tr\u003e\n \u003c/thead\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eAbsolute\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eRelative\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eFinal\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eInitial\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eControl\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eAcute exposure\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e0.52\u0026thinsp;\u0026plusmn;\u0026thinsp;0.03\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e0.36\u0026thinsp;\u0026plusmn;\u0026thinsp;0.04\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e145.69\u0026thinsp;\u0026plusmn;\u0026thinsp;1.42\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e131.4\u0026thinsp;\u0026plusmn;\u0026thinsp;1.51\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eChronic Exposure\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e0.57\u0026thinsp;\u0026plusmn;\u0026thinsp;0.03\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e0.33\u0026thinsp;\u0026plusmn;\u0026thinsp;0.06\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e168.73\u0026thinsp;\u0026plusmn;\u0026thinsp;1.48\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e126.4\u0026thinsp;\u0026plusmn;\u0026thinsp;1.75\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eChronic exposure in food.\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e0.54\u0026thinsp;\u0026plusmn;\u0026thinsp;01\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e0.34\u0026thinsp;\u0026plusmn;\u0026thinsp;0.02\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e161.73\u0026thinsp;\u0026plusmn;\u0026thinsp;0.03\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e133.40\u0026thinsp;\u0026plusmn;\u0026thinsp;0.03\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e10mg/kg Cr\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eAcute exposure\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e0.51\u0026thinsp;\u0026plusmn;\u0026thinsp;0.05\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e0.36\u0026thinsp;\u0026plusmn;\u0026thinsp;0.02\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e140.80\u0026thinsp;\u0026plusmn;\u0026thinsp;1.52\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e127.25\u0026thinsp;\u0026plusmn;\u0026thinsp;1.32\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eChronic Exposure\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e0.58\u0026thinsp;\u0026plusmn;\u0026thinsp;0.05\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e0.37\u0026thinsp;\u0026plusmn;\u0026thinsp;0.02\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e156.80\u0026thinsp;\u0026plusmn;\u0026thinsp;2.66\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e138.25\u0026thinsp;\u0026plusmn;\u0026thinsp;1.84\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eChronic exposure in food.\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e0.60\u0026thinsp;\u0026plusmn;\u0026thinsp;0.01\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e0.38\u0026thinsp;\u0026plusmn;\u0026thinsp;0.01\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e156.73\u0026thinsp;\u0026plusmn;\u0026thinsp;0.02\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e132.28\u0026thinsp;\u0026plusmn;\u0026thinsp;0.02\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e20mg/kg Cr\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eAcute exposure\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e0.53\u0026thinsp;\u0026plusmn;\u0026thinsp;0.10\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e0.37\u0026thinsp;\u0026plusmn;\u0026thinsp;0.02\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e141.75\u0026thinsp;\u0026plusmn;\u0026thinsp;3.50\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e121.75\u0026thinsp;\u0026plusmn;\u0026thinsp;2.91\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eChronic Exposure\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e0.55\u0026thinsp;\u0026plusmn;\u0026thinsp;0.10\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e0.35\u0026thinsp;\u0026plusmn;\u0026thinsp;0.02\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e155.75\u0026thinsp;\u0026plusmn;\u0026thinsp;3.56\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e137.75\u0026thinsp;\u0026plusmn;\u0026thinsp;3.58\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eChronic exposure in food.\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e0.47\u0026thinsp;\u0026plusmn;\u0026thinsp;0.03\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e0.29\u0026thinsp;\u0026plusmn;\u0026thinsp;0.01\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e161.43\u0026thinsp;\u0026plusmn;\u0026thinsp;0.02\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e132.55\u0026thinsp;\u0026plusmn;\u0026thinsp;0.01\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e30mg/kg Cr\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eAcute exposure\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e0.54\u0026thinsp;\u0026plusmn;\u0026thinsp;0.12\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e0.38\u0026thinsp;\u0026plusmn;\u0026thinsp;0.01\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e141.23\u0026thinsp;\u0026plusmn;\u0026thinsp;2.51\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e130.75\u0026thinsp;\u0026plusmn;\u0026thinsp;0.80\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eChronic Exposure\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e0.59\u0026thinsp;\u0026plusmn;\u0026thinsp;0.12\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e0.38\u0026thinsp;\u0026plusmn;\u0026thinsp;0.01\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e153.23\u0026thinsp;\u0026plusmn;\u0026thinsp;3.97\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e135.75\u0026thinsp;\u0026plusmn;\u0026thinsp;0.85\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eChronic exposure in food.\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e0.59\u0026thinsp;\u0026plusmn;\u0026thinsp;0.01\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e0.37\u0026thinsp;\u0026plusmn;\u0026thinsp;0.12\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e160.25\u0026thinsp;\u0026plusmn;\u0026thinsp;0.03\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e136.20\u0026thinsp;\u0026plusmn;\u0026thinsp;0.02\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e15mg/kg dox\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eAcute exposure\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e0.53\u0026thinsp;\u0026plusmn;\u0026thinsp;0.06\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e0.37\u0026thinsp;\u0026plusmn;\u0026thinsp;0.02\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e144.50\u0026thinsp;\u0026plusmn;\u0026thinsp;2.00\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e122.40\u0026thinsp;\u0026plusmn;\u0026thinsp;1.14\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eChronic Exposure\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e0.58\u0026thinsp;\u0026plusmn;\u0026thinsp;0.06\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e0.38\u0026thinsp;\u0026plusmn;\u0026thinsp;0.01\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e159.50\u0026thinsp;\u0026plusmn;\u0026thinsp;2.73\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e126.40\u0026thinsp;\u0026plusmn;\u0026thinsp;1.24\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eChronic exposure in food.\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e0.47\u0026thinsp;\u0026plusmn;\u0026thinsp;0.02\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e0.30\u0026thinsp;\u0026plusmn;\u0026thinsp;0.13\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e156.43\u0026thinsp;\u0026plusmn;\u0026thinsp;0.02\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e135.70\u0026thinsp;\u0026plusmn;\u0026thinsp;0.02\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e20mg/kg dox\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eAcute exposure\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e0.55\u0026thinsp;\u0026plusmn;\u0026thinsp;0.07\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e0.38\u0026thinsp;\u0026plusmn;\u0026thinsp;0.01\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e143.5\u0026thinsp;\u0026plusmn;\u0026thinsp;2.17\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e120.10\u0026thinsp;\u0026plusmn;\u0026thinsp;1.20\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eChronic Exposure\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e0.57\u0026thinsp;\u0026plusmn;\u0026thinsp;0.07\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e0.35\u0026thinsp;\u0026plusmn;\u0026thinsp;0.01\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e163.5\u0026thinsp;\u0026plusmn;\u0026thinsp;2.15\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e124.00\u0026thinsp;\u0026plusmn;\u0026thinsp;1.68\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eChronic exposure in food.\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e0.47\u0026thinsp;\u0026plusmn;\u0026thinsp;0.01\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e0.30\u0026thinsp;\u0026plusmn;\u0026thinsp;0.01\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e156.15\u0026thinsp;\u0026plusmn;\u0026thinsp;0.03\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e132.83\u0026thinsp;\u0026plusmn;\u0026thinsp;0.01\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n \u003ctfoot\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"6\"\u003eEach value represents the mean\u0026thinsp;\u0026plusmn;\u0026thinsp;SE; Values are significantly different at P\u0026thinsp;\u0026lt;\u0026thinsp;0.05.\u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tfoot\u003e\n \u003c/table\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/div\u003e\n\u003cp\u003eIt was also deduced in this study that the Cr6\u0026thinsp;+\u0026thinsp;exposure through the administration of K\u003csub\u003e2\u003c/sub\u003eCr\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e7\u003c/sub\u003e in all the treatment phases induced oxidative damage to the heart, as evident in the decrease of antioxidants activities (SOD, CAT, and Gpx). The antioxidant enzymes assessed in this study, as seen in Fig. \u003cspan class=\"InternalRef\"\u003e1\u003c/span\u003e (A), revealed a statistically marked decrease in the antioxidant activities of GPx, SOD and CAT in phase 1 compared to the Normal Control. Also, animal groups treated with Dox showed a significant decrease in GPx, SOD, and CAT compared to the control group. These enzymatic antioxidants are the primary defence blocks that mop out the toxicity effect of the overwhelming oxidant production arising from K\u003csub\u003e2\u003c/sub\u003eCr\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e6\u003c/sub\u003e and Dox exposure. The weak antioxidant defences in the heart make it a porous target compared to other organs (Abarikwu et al., \u003cspan class=\"CitationRef\"\u003e2016\u003c/span\u003e; Boriskin et al.,2020; Ankita et al., \u003cspan class=\"CitationRef\"\u003e2019\u003c/span\u003e Sharifi-Rad et al.,2020). Hence, SOD, CAT, and GPx activities are impaired, resulting in cellular lipids, proteins, and DNA damage and the onset of many chronic diseases. Also, the trend of Oxidant production was observed to be on the increase as the concentrations of both K\u003csub\u003e2\u003c/sub\u003eCr\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e6\u003c/sub\u003e and doxorubicin treatments increased, resulting in a decrease in the antioxidant enzyme activities (GPx, CAT, and SOD) due to the overwhelming burden of the toxic agents (Boriskin et al.,2020; Wuri et al.2022).\u003c/p\u003e\n\u003cp\u003eIn Phase 2, the antioxidant enzymes shown in Fig. \u003cspan class=\"InternalRef\"\u003e1\u003c/span\u003e (B) indicated a similar trend in the decreased SOD, CAT, and GPx activities of the rats exposed to different doses of K\u003csub\u003e2\u003c/sub\u003eCr\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e7\u003c/sub\u003e and Dox for 60days. The percentage decrease in the enzyme activities was higher than the decrease observed in the first treatment phase. This may result from the longer duration of the animal exposure to K\u003csub\u003e2\u003c/sub\u003eCr\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e7\u003c/sub\u003e, compromising the antioxidant defence system and resulting in cardio-damages (Krishnamurthy \u003cem\u003eet al.\u003c/em\u003e,2015; Abarikwu et al., \u003cspan class=\"CitationRef\"\u003e2016\u003c/span\u003e; Ankita et al.,2019; Sharifi-Rad et al.,2020; Fagundes et al.,2022).\u003c/p\u003e\n\u003cp\u003eSimilarly, Phase 3 presented in Fig. \u003cspan class=\"InternalRef\"\u003e1\u003c/span\u003e (C) shows a decrease in the antioxidant activities of GPx, SOD and CAT in rats treated with different doses of K\u003csub\u003e2\u003c/sub\u003eCr\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e7\u003c/sub\u003e supplemented in diets and Dox for 60days. The percentage decrease in antioxidant enzymes observed in rats in the second phase of treatment by oral gavage administration was significantly higher than in the third phase by diet supplementation (Foster et al.,2015). Our findings agree with (Foster et al.,2015), whose results propose that bolus gavage administration of manganese could be associated with higher brain manganese levels and, consequently, a higher risk of neurotoxicity. Therefore, this present study suggests that the higher cardiotoxicity effect observed in the oral Gavage- K\u003csub\u003e2\u003c/sub\u003eCr\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e7\u003c/sub\u003e treated rats compared to the supplemented diet- K\u003csub\u003e2\u003c/sub\u003eCr\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e7\u003c/sub\u003e treated rats may be responsible for the higher decreased antioxidant activities. These observations have raised concerns regarding the fitness of oral treatment administration using Gavage against diet supplementation due to the endocrine disruptor effects observed by the gavage method (Vandenberg et al., \u003cspan class=\"CitationRef\"\u003e2014\u003c/span\u003e; Foster et al.,2015).\u003c/p\u003e\n\u003cp\u003eSecondly, the increased MDA levels observed in all the phases in this present study, as evident in Fig. \u003cspan class=\"InternalRef\"\u003e2\u003c/span\u003e, further reiterate that Rats\u0026apos; treatment with different doses of K\u003csub\u003e2\u003c/sub\u003eCr\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e7\u003c/sub\u003e and Dox induced oxidative stress. The prevalence of MDA in Cr(VI) treated rats is attributable to lipid peroxidation and an increase in ROS production induced by the K\u003csub\u003e2\u003c/sub\u003eCr\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e7\u003c/sub\u003e treatments, thus degrading polyunsaturated lipids or fatty acids in the rats\u0026apos; perturbed biological system; hence may be responsible for the increased levels of MDA observed in this study (Farrokhian et al., \u003cspan class=\"CitationRef\"\u003e2019\u003c/span\u003e; Anam \u0026amp; Purwanto,2020).Also, Dox has proven to generate cardio-dysfunctions through the induction of free radicals such as oxyanions, hydroxyl, and hydrogen peroxide (Teraoka et al., \u003cspan class=\"CitationRef\"\u003e2000\u003c/span\u003e; Bhardwa \u003cem\u003eet al.\u003c/em\u003e, 2011; Hardik et al., \u003cspan class=\"CitationRef\"\u003e2013\u003c/span\u003e). Hence, increased MDA levels were observed.\u003c/p\u003e\n\u003cp\u003eResearchers have also elucidated the elevation of Cardiac markers such as AST, LDH, CK\u0026ndash;MB used as indicators of myocardial tissue damage. These includes ischemia and infarction (Wagner,2003; Yang et al., \u003cspan class=\"CitationRef\"\u003e2014\u003c/span\u003e; Fernandez-Chas et al., \u003cspan class=\"CitationRef\"\u003e2018\u003c/span\u003e; Al-Malky et al.,2019, Lakhani et al.,2021; Firoozichahak et al., \u003cspan class=\"CitationRef\"\u003e2022\u003c/span\u003e). Figure \u003cspan class=\"InternalRef\"\u003e3\u003c/span\u003e (A) in this present study indicated the Cardiotoxicity of K\u003csub\u003e2\u003c/sub\u003eCr\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e7\u003c/sub\u003e and Dox exposure as evidenced in the increased LDH, AST, and CK-MB activities in the phase 1 compared to the control rats. The increased levels observed may be associated with severe Cardiotoxic symptoms such as chest pain, hypertension, decreased heart function, myocarditis, cardiomyopathy, shortness of breath, arrhythmias, palpitations, vascular disease, acute coronary syndrome, oedema, and vasculitis (Gaze \u003cspan class=\"CitationRef\"\u003e2007\u003c/span\u003e; Ganatra et al.,2019; Mehta et al., Patel et al.,2021; Firoozichahak et al., \u003cspan class=\"CitationRef\"\u003e2022\u003c/span\u003e). Similar results were also observed in our findings in both the second treatment phase (Fig. \u003cspan class=\"InternalRef\"\u003e3\u003c/span\u003e (B)) and the Third treatment phase (Fig. \u003cspan class=\"InternalRef\"\u003e3\u003c/span\u003e (C). There was a significant percentage increase in LDH, AST and CK-MB activities of the K\u003csub\u003e2\u003c/sub\u003eCr\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e7\u003c/sub\u003e treated rats in the gavage-treated and diet-supplemented rats relative to the control group. However, the percentage increase was higher in the former, probably indicating that longer treatment with different doses of K\u003csub\u003e2\u003c/sub\u003eCr\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e7\u003c/sub\u003e and Dox exposed the Rats to progressive Cardiotoxicity. The higher increase observed in the myocardial markers may be due to the mode of treatment administration, which suggested severe cardiotoxicity induction through gavage administration (Foster et al.,2015; Zhai et al.,2019).\u003c/p\u003e\n\u003cp\u003eFurthermore, CTnI, a quintessential and highly sensitive cardio-biomarker consisting of regulatory proteins controlling the calcium-mediated interaction of myosin and actin during myocyte contraction (Park et al., \u003cspan class=\"CitationRef\"\u003e2017\u003c/span\u003e; Chen et al.,2019, Chaulin, \u003cspan class=\"CitationRef\"\u003e2021\u003c/span\u003e). Figure \u003cspan class=\"InternalRef\"\u003e4\u003c/span\u003e in this present study indicates a higher percentage increase in levels of CTnI in all the treatment phases relative to the control groups. The percentage increase progressed with increased duration of the K\u003csub\u003e2\u003c/sub\u003eCr\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e7\u003c/sub\u003e exposure, i.e., 21days and 60days, respectively, compared to the control rats. The Dox groups similarly showed an increase in CTnI, indicating that both K\u003csub\u003e2\u003c/sub\u003eCr\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e7\u003c/sub\u003e and Dox may be implicated in a dose and duration-dependent cardiotoxicity. CTnI changes in concentration levels are useful in diagnosing heart failure and other related cardiac diseases (Magnussen \u0026amp; Blankenberg., 2018). Clinical evidence has shown that patients who are often readmitted due to heart failure are those with persistent CTnI increases (Magnussen \u0026amp; Blankenberg., 2018).\u003c/p\u003e\n\u003cp\u003eSimilarly, CRP levels in this present study, as shown in Fig. \u003cspan class=\"InternalRef\"\u003e5\u003c/span\u003e, indicated spikes in its levels in K\u003csub\u003e2\u003c/sub\u003eCr\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e7\u003c/sub\u003e and Dox-treated rats in all the phases compared to the control groups. However,the percentage increases were significantly elevated in the second and third phases, possibly due to the longer treatment duration compared to the first phase. CRP are pro-inflammatory markers produced by the liver and used clinically to diagnose heart failure. Research pieces of evidence support that there may have occurred intestinal hypoperfusion due to the translocation of K\u003csub\u003e2\u003c/sub\u003eCr\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e7\u003c/sub\u003e oral administration from the stomach into the bloodstream resulting in vascular inflammation and subsequent increased levels of CRP observed in this study (Anand et al., \u003cspan class=\"CitationRef\"\u003e2005\u003c/span\u003e; Magnussen \u0026amp; Blankenberg, \u003cspan class=\"CitationRef\"\u003e2018\u003c/span\u003e; Vulesevic et al.,2019).\u003c/p\u003e\n\u003cp\u003eAlso, in this present study, Fig. \u003cspan class=\"InternalRef\"\u003e6\u003c/span\u003e indicated significant decreases in the levels of NO availability in the hearts of the K\u003csub\u003e2\u003c/sub\u003eCr\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e7\u003c/sub\u003e and Dox treated Rats in the first phase compared to the normal Control. In contrast, an increase was observed in the second and third treatment phases. Many research findings has stated that NO is synthesized by a family of nitric oxide synthases with three isoforms, which include inducible (iNOS), neuronal (nNOS), and endothelial NOS (eNOS). While iNOS is upregulated in activated macrophages, nNOS is primarily expressed in the neural tissue, and eNOS abounds in the endothelium, diffuses to the smooth muscles and enables the endothelial vascular homeostasis, which controls dilation or constriction through the activation of soluble guanylyl cyclase-cGMP-dependent protein kinase pathway. In addition, the impairment of NO synthesis is pertinent in the diagnosis of chronic heart failure, coronary artery diseases, arteriosclerosis involving stable and unstable angina and myocardial infarction hypertension, and as well pulmonary arterial hypertension, which progresses to the right ventricle failure ( Ferlito, \u003cspan class=\"CitationRef\"\u003e2000\u003c/span\u003e; Silva-Costa-Gomes; Dunham-Snary et al. \u003cspan class=\"CitationRef\"\u003e2017\u003c/span\u003e; Frump et al., \u003cspan class=\"CitationRef\"\u003e2018\u003c/span\u003e; Kurakula et al.,2021 Finkelman et al.,2017; Tran et al.,2022). The discrepancy observed in NO levels in all treatment phases compared to the normal Control may be due to an overexpression of iNOS, whose induction occurs primarily in conjunction with infection and inflammation as part of the defence response. iNOS expression is minimal under normal conditions; however, it is upregulated in response to pro-inflammatory cytokines and thus generates much more NO than eNOS does. Hence, High NO levels may have occurred in response to inflammation due to K\u003csub\u003e2\u003c/sub\u003eCr\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e7\u003c/sub\u003e exposure for 60 days, while the decrease in NO levels in the groups treated with K\u003csub\u003e2\u003c/sub\u003eCr\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e7\u003c/sub\u003e and Dox may have resulted from the inhibition of eNOS expression due to treatment exposure for 21 days. Thus, signalling cardiotoxicity owing to the development of systemic and pulmonary hypertension, which plays a key role in the pathophysiology of heart-related ailments (Wu et al., \u003cspan class=\"CitationRef\"\u003e2021\u003c/span\u003e). Furthermore, the increase in NO levels in the DOx treated groups as seen in this study, especially in the second and third phases, indicates an upregulation of nitric oxide synthase activities as observed by other researchers leading to an increase in the concentration of nitric oxide, thereby enhancing the production of the highly toxic peroxynitrite (Wu et al., \u003cspan class=\"CitationRef\"\u003e2021\u003c/span\u003e).\u003c/p\u003e\n\u003cp\u003eA report by Lee et al.(2016) has shown that NOS can play compensatory roles in laboratory animals with one or two disrupted isoforms. For example, the up-regulation of nNOS expression compensated the non-expression of eNOS and vice versa. These strides promises a useful research tool to enhance a discreet interpretation of discrepancies in NO availability and disease prognosis.\u003c/p\u003e\n\u003cp\u003eThe histopathological examination in Fig. \u003cspan class=\"InternalRef\"\u003e7\u003c/span\u003e shows the Effect of K\u003csub\u003e2\u003c/sub\u003eCr\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e7\u003c/sub\u003e treatment in phase 1, revealing control rats(a) as having the normal histoarchitecture of the heart, as the myocardium showed a rich network of vasculature, capillaries, nucleus, and pericytes. In contrast, the groups treated with K\u003csub\u003e2\u003c/sub\u003eCr\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e7\u003c/sub\u003e (b, c and d) indicated areas of mild tissue oedema due to treatments exposure suggesting the pathogenesis of lung oedema due to K\u003csub\u003e2\u003c/sub\u003eCr\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e7\u003c/sub\u003e induced Cardiotoxicity resulting from pulmonary hypertension from hypoxic pulmonary vasoconstriction induced by Cr(VI) agents resulting in congestive heart failure ( Dunham-Snary et al. \u003cspan class=\"CitationRef\"\u003e2017\u003c/span\u003e). The Dox groups (e and f) showed a higher degree of cardiac damage as there was myotocytolysis and hyaline necrosis in addition to pulmonary oedema, the affected cells\u0026apos; loss of striation, fragmentation of the myocytes, intense eosinophilic staining of the sarcoplasm (myocytes cytoplasm) with nuclear pyknosis and karyorrhexis. In group 6, oedema seemed to be more severe and widespread.\u003c/p\u003e\n\u003cp\u003eSimilarly, Figs. \u003cspan class=\"InternalRef\"\u003e8\u003c/span\u003e and 9 revealed the histopathology examination of K\u003csub\u003e2\u003c/sub\u003eCr\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e7\u003c/sub\u003e and Dox treated Rats in phase 2 and 3 showing Control groups (g and m, respectively) expressed a normal heart structure while (h, I, j) and (n, o, p) indicated areas of myocyte displaced, indicating pulmonary oedema; Dox groups (k and l) and (q and r) similarly showed areas of pulmonary oedema, hyaline necrosis and myocytolysis for the second and third study, respectively. Pulmonary oedema has been of interest to cardiologists, and pulmonologists, due to its prevalence in the onset of heart diseases.\u003c/p\u003e\n\u003cp\u003ePulmonary oedema is induced by the movement of fluid extravascularly into the interstitium and alveoli of the lungs. The most common causes of pulmonary oedema are Cardiomyopathy, Aortic valve disease, coronary heart disease, hypertension, mitral valve disease,` and congestive heart disease. Other causes include damage to the lungs, kidneys, pancreas, drugs, trauma, and toxins toxins (Ingbar, D. H.,2019; Logan et al.,2019., Barile, \u003cspan class=\"CitationRef\"\u003e2020\u003c/span\u003e Moreno-Gonzalez et al.,2022).. Furthermore, Many researchers categorized pulmonary oedema into permeability oedema (with and without diffuse alveolar damage (DAD), hydrostatic pressure oedema, and mixed oedema, where there is both an increase in membrane permeability and hydrostatic pressure (Paone et al.,2018; Zompatori et al., \u003cspan class=\"CitationRef\"\u003e2014\u003c/span\u003e; Barile, \u003cspan class=\"CitationRef\"\u003e2020\u003c/span\u003e; Matthay et al., 2019; Carlicchi et al., \u003cspan class=\"CitationRef\"\u003e2021\u003c/span\u003e; Ingbar, D. H. (\u003cspan class=\"CitationRef\"\u003e2019\u003c/span\u003e). However, it is not clear which physiologic category of the pulmonary oedema observed in this study due to the K\u003csub\u003e2\u003c/sub\u003eCr\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e7\u003c/sub\u003e treatments.\u003c/p\u003e"},{"header":"Conclusion","content":"\u003cp\u003eThus, this study demonstrated that Cr [VI] compared well with Dox in cardiotoxicity induction with accompanying oxidative stress, inflammatory and histo-hepatic responses in the rats. The dose and duration of treatments for the biochemical and myocardial indices are not dependent on body weight alone, hence may need pharmacokinetic modifications for conversion between animals and humans. Also, the mechanism that resulted in pulmonary oedema regarding the myocardial indices observed in this study is unclear warranting further studies for clarification.\u003c/p\u003e"},{"header":"Declarations","content":"\u003cp\u003e\u003cstrong\u003eFunding\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe authors did not receive support from any organization for the submitted work.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFinancial interests\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe authors declare they have no financial interests.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompeting Interest\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe authors have no competing interests to declare that are relevant to the content of this article.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eEthics approval and consent to participate\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eAll investigations involving the experimental animals adhered strictly to the guidelines for the care and use of animals as defined by the National Institute of Health Guide for the Care and Use of Laboratory Animals. Committee on Care and Use of Laboratory Animals, US Department of Health and Human Services, Public Health Service, Institute of Laboratory Animal Resources, USA. The experiment protocols were performed after the ethical approval was granted by the College of Natural Science, Research Ethics Committee (CREC/002/21), Michael Okpara University of Agriculture.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eConsent for publication\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eNot applicable\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAvailability of data and material\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eAll data generated or analyzed during this study are included in this published article. Any further reasonable request can be made through the corresponding author.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthors\u0026apos; contributions\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eConceptualization: Onyedikachi, Uchechi Bliss, Awah, Favour Matthew; Kpobari Nkpaa, Methodology: Onyedikachi Uchechi Bliss, Kpobari Nkpaa, Egbuonu Anthony Cemaluk Chinedum; Awah Favour Matthew Formal analysis and investigation: Onyedikachi,Uchechi Bliss, Awah Favour Matthew; Writing - original draft preparation: Onyedikachi Uchechi Bliss; Awah Favour Matthew.; Writing - review and editing: Onyedikachi Uchechi Bliss; Ijioma,Solomon Nnah ;Egbuonu, Anthony Cemaluk Chinedum; Resources: Onyedikachi,Uchechi Bliss; Awah, Favour Matthew.; Supervision: Egbuonu, Anthony Cemaluk Chinedum, Ijioma, Solomon Nnah.\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\n\u003cli\u003eAbarikwu, S. O.,Duru, Q. C.Chinonso, O. V and Njoku, R.C. (2016). Antioxidant enzymes activity, lipid peroxidation, oxidative damage in the testis and epididymis, and steroidogenesis in rats after co-exposure to atrazine and ethanol. Andrologia, 48(5): 548-557.\u003c/li\u003e\n\u003cli\u003eAbdelatty, A., Ahmed, M. S., Abdel-Kareem, M. A., Dmerdash, M., Mady, R., Saad, A. S., Albrakat, A, Elmahallawy,E. K, Elsawak, A \u0026amp; Abdo, W. (2021). Acute and Delayed Doxorubicin-Induced Myocardiotoxicity Associated with Elevation of Cardiac Biomarkers, Depletion of Cellular Antioxidant Enzymes, and Several Histopathological and Ultrastructural Changes. \u003cem\u003eLife\u003c/em\u003e, \u003cem\u003e11\u003c/em\u003e(9), 880. doi: 10.3390/life11090880.\u003c/li\u003e\n\u003cli\u003eAdjroud, O. (2009).effects of potassium dichromate on haematological parametrs in female and male Wistar albino rats. \u003cem\u003eAss. University Bulletin of Environmental Research 12\u003c/em\u003e(2), 87-98.\u003c/li\u003e\n\u003cli\u003eAgency for Toxic Substances and Disease Registry.ATSDR. (2012). Toxicological profile for chromium. US Public Health Service, Agency for Toxic Substances and Disease Registry. 592.\u003c/li\u003e\n\u003cli\u003eAhmad, M. K., Syma, S., \u0026amp; Mahmood, R. (2011). Cr (VI) induces lipid peroxidation, protein oxidation and alters the activities of antioxidant enzymes in human erythrocytes. \u003cem\u003eBiological trace element research\u003c/em\u003e, \u003cem\u003e144\u003c/em\u003e(1), 426-435.\u003c/li\u003e\n\u003cli\u003eAl-Malky, H.S., Osman, A.M., Damanhouri, Z.A., Alkreathy, H.M., Al Aama, J.Y., Ramadan, W.S., Al Qahtani, A.A., Al Mahdi, H.B. (2019). Modulation of doxorubicin-induced expression of the multidrug resistance gene in breast cancer cells by diltiazem and protection against Cardiotoxicity in experimental animals. Cancer Cell International, 19, 191. doi: 10.1186/s12935-019-0912-0. \u003c/li\u003e\n\u003cli\u003eAnam, SC \u0026amp; Purwanto, B. (2020). Acute response moderate intensity treadmill training on decrease malondialdehyde in obesity women. \u003cem\u003eSTRADA Jurnal IImiah Kesehatan\u003c/em\u003e, \u003cem\u003e9\u003c/em\u003e(2), 358-367. \u003c/li\u003e\n\u003cli\u003eAnand, I. S., Latini, R., Florea, V. G., Kuskowski, M. A., Rector, T., Masson, S., ... \u0026amp; Cohn, J. N. (2005). C-reactive protein in heart failure: prognostic value and the effect of valsartan. \u003cem\u003eCirculation\u003c/em\u003e, \u003cem\u003e112\u003c/em\u003e(10), 1428-1434.\u003c/li\u003e\n\u003cli\u003eAnderson, H.C. \u0026amp; Mccarthy, M. (1950). Determination of C-reactive protein in the blood as a measure of the activity of the disease process in acute rheumatic fever. \u003cem\u003eThe American Journal of Medicine\u003c/em\u003e, \u003cem\u003e8\u003c/em\u003e(4),445-455.\u003c/li\u003e\n\u003cli\u003eAnkita, N., Liang-jun, Y., chanda,K. J, Nilanjana, D.(2019). Role of Catalase in oxidative stress and age associated degenerative diseases. 2019:9613090\u003c/li\u003e\n\u003cli\u003eArivarasu, N. A., Fatima, S., \u0026amp; Mahmood, R. (2008). Oral administration of potassium dichromate inhibits brush border membrane enzymes and alters antioxidant status of rat intestine. \u003cem\u003eArchives of toxicology\u003c/em\u003e, \u003cem\u003e82\u003c/em\u003e(12), 951-958. \u003c/li\u003e\n\u003cli\u003eArthur, J. R and Boyne, R. (1985). Superoxide dismutase and glutathione peroxidase activities in neutrophil from selenium deficient and copper deficient cattle. \u003cem\u003eLife Sciences\u003c/em\u003e, \u003cem\u003e36,\u003c/em\u003e1569-1575.\u003c/li\u003e\n\u003cli\u003eAwasthi, Y., Ratn, A., Prasad, R., Kumar, M., \u0026amp; Trivedi, S. P. (2018). An in vivo analysis of Cr6+ induced biochemical, genotoxicological and transcriptional profiling of genes related to oxidative stress, DNA damage and apoptosis in liver of fish, Channa punctatus (Bloch, 1793). \u003cem\u003eAquatic toxicology\u003c/em\u003e, \u003cem\u003e200\u003c/em\u003e, 158-167.\u003c/li\u003e\n\u003cli\u003eBagchi, D., Stohs, S \u0026amp; Downs, B. (2002). Cytotoxicity and oxidative mechanisms of different forms of chromium. Toxicology, 180:5\u0026ndash;22. https://doi.org/10.1016/s0300-483x(02)00378-5 \u003c/li\u003e\n\u003cli\u003eBarile M. (2020). Pulmonary Oedema: A Pictorial Review of Imaging Manifestations and Current Understanding of Mechanisms of Disease. \u003cem\u003eEuropean journal of radiology open\u003c/em\u003e, \u003cem\u003e7\u003c/em\u003e, 100274. https://doi.org/10.1016/j.ejro.2020.100274 \u003c/li\u003e\n\u003cli\u003eBhardwaj, A., Singh, S., Srivastava, S. K.Honkanen, R. E., Reed, E and Singh, A. P. (2011). Modulation of Protein Phosphatase 2A Activity Alters Androgen-Independent Growth of Prostate Cancer Cells: Therapeutic Implications. \u003cem\u003eMolecular Cancer Therapy\u003c/em\u003e, \u003cem\u003e10\u003c/em\u003e, 720\u0026ndash;731.\u003c/li\u003e\n\u003cli\u003eBiondo, L.A., Lima, J.E.A., Souza, C.O., Cruz, M.M., Cunha, R.D.C., Alonso-Vale, M.I., Oyama, L. M., Nascimento, C. M. O., Pimentel,G.D., dos Santos, R.V. T. , Lira, F. S., Neto, J C. R. (2016). Impact of Doxorubicin Treatment on the Physiological Functions of White Adipose Tissue. \u003cem\u003ePLoS ONE,\u003c/em\u003e \u003cem\u003e11\u003c/em\u003e(3): e0151548. doi:10.1371/journal.pone.0151548 \u003c/li\u003e\n\u003cli\u003eBoriskin, P., Gulenko, O., Devyatkin, A., Karimova, R., Leonov, V., \u0026amp; Pavlova, O. (2020). Correlation of the distribution of antioxidant enzyme concentrations in blood serum and heart tissue in rats. In BIO Web of Conferences, EDP Sciences (Vol. 17, p. 00234). DOI:10.1051/bioconf/20201700234\u003c/li\u003e\n\u003cli\u003eCarlicchi, E., Gemma, P., Poerio, A., Caminati, A., Vanzulli, A., \u0026amp; Zompatori, M. (2021). Chest-CT mimics of COVID-19 pneumonia\u0026mdash;a review article. \u003cem\u003eEmergency Radiology\u003c/em\u003e, \u003cem\u003e28\u003c/em\u003e(3), 507-518.s\u003c/li\u003e\n\u003cli\u003eCarvalho, F. A.,Burgeiro, R., Garcia, A., Moreno, R. and Carvalho, P. O. (2014). Doxorubicin-induced Cardiotoxicity: from bioenergetic failure and cell death to cardiomyopathy.\u003cem\u003e Medical Research Review\u003c/em\u003e. 34, 106\u0026ndash;135. doi: 10.1002/med.21280 \u003c/li\u003e\n\u003cli\u003eChaulin, A. M. (2021). Elevation mechanisms and diagnostic consideration of cardiac troponins under conditions not associated with myocardial infarction. Part 1. \u003cem\u003eLife\u003c/em\u003e, \u003cem\u003e11\u003c/em\u003e(9), 914.\u003c/li\u003e\n\u003cli\u003eChen, Y., Tao, Y., Zhang, L., Xu, W., \u0026amp; Zhou, X. (2019). Diagnostic and prognostic value of biomarkers in acute myocardial infarction. \u003cem\u003ePostgraduate medical journal\u003c/em\u003e, \u003cem\u003e95\u003c/em\u003e(1122), 210-216.\u003c/li\u003e\n\u003cli\u003eDas, A. C., Sultana, R and Sultana, M. S. (2015).Impact of tannert on worker\u0026apos;\u0026apos;sreproductivehealth in the area of Hazaribagh in Dhaka, Bangladesh. \u003cem\u003eInternational Journal Research\u003c/em\u003e. 2(6), 159-181.\u003c/li\u003e\n\u003cli\u003eDas, P. K., Das, B. P., \u0026amp; Dash, P. (2021). Chromite mining pollution, environmental impact, toxicity and phytoremediation: a review. \u003cem\u003eEnvironmental Chemistry Letters\u003c/em\u003e, \u003cem\u003e19\u003c/em\u003e(2), 1369-1381.\u003cem\u003e DOI: \u003c/em\u003e\u003cem\u003e10.1007/s10311-020-01102-w\u003c/em\u003e\u003c/li\u003e\n\u003cli\u003eDe Almeida, R. P., Ferrari, R. G., Kato, L. S., Hauser-Davis, R. A., \u0026amp; Conte-Junior, C. A. (2021). A Systematic Review on Metal Dynamics and Marine Toxicity Risk Assessment Using Crustaceans as Bioindicators. \u003cem\u003eBiological Trace Element Research\u003c/em\u003e, 1-23.\u003c/li\u003e\n\u003cli\u003eDessy, C. \u0026amp; Ferron, O. (2004). Pathophysiological Roles of Nitric Oxide: In the Heart and the Coronary Vasculature. \u003cem\u003eCurrent Medical Chemistry \u0026ndash; Anti- Inflammatory and Anti-Allergy Agents in Medicinal Chemistry\u003c/em\u003e, \u003cem\u003e3\u003c/em\u003e (3), 207\u0026ndash; 216. \u003c/li\u003e\n\u003cli\u003eDunham-Snary, K. J., Wu, D., Sykes, E. A., Thakrar, A., Parlow, L. R., Mewburn, J. D., Parlow, J.L., Archer, S. L. (2017). Hypoxic pulmonary vasoconstriction: from molecular mechanisms to medicine. \u003cem\u003eChest\u003c/em\u003e, \u003cem\u003e151\u003c/em\u003e(1), 181-192. doi: 10.1016/j.chest.2016.09.001.\u003c/li\u003e\n\u003cli\u003eEl-Demerdash, F. M., El-Sayed, R. A., \u0026amp; Abdel-Daim, M. M. (2021). Rosmarinus officinalis essential oil modulates renal toxicity and oxidative stress induced by potassium dichromate in rats. \u003cem\u003eJournal of Trace Elements in Medicine and Biology\u003c/em\u003e, \u003cem\u003e67\u003c/em\u003e, 126791.\u003c/li\u003e\n\u003cli\u003eErbaş, O., Altuntaş, İ., \u0026Ccedil;ağlar, \u0026Ouml;., \u0026Ouml;zyilmaz, E., Sari, E., \u0026Uuml;z\u0026uuml;mc\u0026uuml;, İ., \u0026amp; Erbakan, K. (2022). Experimental Model of Cardiotoxicity. In (Ed.), Risk Factors for Cardiovascular Disease. \u003cem\u003eIntechOpen\u003c/em\u003e. https://doi.org/10.5772/intechopen.101401\u003c/li\u003e\n\u003cli\u003eFagundes, B. H. F., Nascimento, P. C., Arag\u0026atilde;o, W. A. B., Chemelo, V. S., Bittencourt, L. O., Eir\u0026oacute;-Quirino, L., Silva, M.C.F., Freire, M.A.M., Fernandes, L.M.P., Maia, C.S.F., Crespo-Lopez, M. E., Lima, R. R. (2022). Methylmercury exposure during prenatal and postnatal neurodevelopment promotes oxidative stress associated with motor and cognitive damages in rats: an environmental-experimental toxicology study. \u003cem\u003eToxicology reports\u003c/em\u003e, \u003cem\u003e9\u003c/em\u003e, 563-574. https://doi.org/10.1016/j.toxrep.2022.02.014\u003c/li\u003e\n\u003cli\u003eFarrokhian, A., Raygan, F., Soltani, A., Tajabadi-Ebrahimi, M., Sharifi Esfahani, M., Karami, A. A., \u0026amp; Asemi, Z. (2019). The effects of synbiotic supplementation on carotid intima-media thickness, biomarkers of inflammation, and oxidative stress in people with overweight, diabetes, and coronary heart disease: A randomized, double-blind, placebo-controlled trial. Probiotics and antimicrobial proteins, 11(1), 133-142.\u003c/li\u003e\n\u003cli\u003eFerlito, S.(2000). Cardiovascular diseases and nitric oxide in humans. Minerva Cardioangiol. Nov;\u003cem\u003e48\u003c/em\u003e(11),379-86. \u003c/li\u003e\n\u003cli\u003eFernandez-Chas, M., Curtis, M.J., Niederer, A.S. (2018). Mechanism of Doxorubicin cardiotoxicity evaluated by integrating multiple molecular effects into a biophysical model. \u003cem\u003eBr. J. Pharmacol\u003c/em\u003e., \u003cem\u003e175\u003c/em\u003e, 763\u0026ndash;781.\u003c/li\u003e\n\u003cli\u003eFinkelman, B. S., Putt, M., Wang, T., Wang, L., Narayan, H., Domchek, S., ... \u0026amp; Ky, B. (2017). Arginine-nitric oxide metabolites and cardiac dysfunction in patients with breast cancer. \u003cem\u003eJournal of the American College of Cardiology\u003c/em\u003e, \u003cem\u003e70\u003c/em\u003e(2), 152-162. doi: 10.1016/j.jacc.2017.05.019\u003c/li\u003e\n\u003cli\u003eFiroozichahak, A., Rahimnejad, S., Rahmani, A., Parvizimehr, A., Aghaei, A., \u0026amp; Rahimpoor, R. (2022). Effect of occupational exposure to lead on serum levels of lipid profile and liver enzymes: An occupational cohort study. \u003cem\u003eToxicology reports\u003c/em\u003e, \u003cem\u003e9\u003c/em\u003e, 269-275. doi: 10.1016/j.toxrep.2022.02.009. \u003c/li\u003e\n\u003cli\u003eFoster, M.L., Bartnikas, T.B., Johnson, L.C., Herrera, C., Pettiglio, M.A., Keene, A.M., Taylor, M.D., Dorman, D.C. ( 2015). Pharmacokinetic evaluation of the equivalency of Gavage, dietary, and drinking water exposure to manganese in F344 rats. Toxicological Science, 145(2),244-51. https://doi.org/10.1093/toxsci/kfv047 \u003c/li\u003e\n\u003cli\u003eFrump, A. L., Bonnet, S., de Jesus Perez, V. A., \u0026amp; Lahm, T. (2018). Emerging role of angiogenesis in adaptive and maladaptive right ventricular remodeling in pulmonary hypertension. \u003cem\u003eAmerican Journal of Physiology-Lung Cellular and Molecular Physiology\u003c/em\u003e, \u003cem\u003e314\u003c/em\u003e(3), L443-L460. DOI: 10.1152/ajplung.00374.2017 \u003c/li\u003e\n\u003cli\u003eFurihata, T., Maekawa, S., Takada, S, Kakutani, N., Nambu, H., Shirakawa, R.,\u003c/li\u003e\n\u003cli\u003eGad, S. C. (2015). Cardiovascular toxicology and its evaluation. \u003cem\u003eMammalian Toxicology\u003c/em\u003e, 425-452. https://doi.org/10.1002/9781118683484.ch19 \u003c/li\u003e\n\u003cli\u003eGanatra S, Parikh R, Neilan, T.G.(2019). Cardiotoxicity of immune therapy. Cardiol Clin. , 37(4), 385\u0026ndash;97. https://doi.org/10.1016/j.ccl.2019.07.008.\u003c/li\u003e\n\u003cli\u003eGarc\u0026iacute;a-Ni\u0026ntilde;o, W. R.,Zatarain-Barr\u0026oacute;n, Z. L.,Hern\u0026aacute;ndez-Pando, R.,Vega-Garc\u0026iacute;a, C. C.Tapia, Eand Pedraza-Chaverri, J. (2015). Oxidative Stress Markers and Histological Analysis in Diverse Organs from Rats Treated with a Hepatotoxic Dose of Cr(VI): Effect of Curcumin. \u003cem\u003eBiological Trace Element and Research.\u003c/em\u003e, 167(1), 130-45. https://doi.org/10.1007/s12011-015-0283-x \u003c/li\u003e\n\u003cli\u003eGaze, D. C. (2007). The role of existing and novel cardiac biomarkers for cardioprotection. \u003cem\u003eCurrent Opinion in Investigational Drugs,\u003c/em\u003e \u003cem\u003e8 \u003c/em\u003e(9), 711-717.\u003c/li\u003e\n\u003cli\u003eGutteridge, J. M. (1995). Lipid peroxidation and antioxidants as biomarkers of tissue damage. \u003cem\u003eClinical Chemistry,\u003c/em\u003e \u003cem\u003e41\u003c/em\u003e(12 Pt 2), 1819-1828. \u003c/li\u003e\n\u003cli\u003eGuven, C., Sevgiler, Y., \u0026amp; Taskin, E. (2018). Mitochondrial dysfunction associated with Doxorubicin. \u003cem\u003eMitochondrial Disease\u003c/em\u003e, \u003cem\u003e323\u003c/em\u003e. DOI: 10.5772/intechopen.80284.\u003c/li\u003e\n\u003cli\u003eHardaway,B.W (2019). Adriamycin-associated cardiomyopathy: where are we now?updates in pathophysiology, dose recommendations, prognosis, and outcomes.\u003cem\u003eCurrent Opinion Cardiology.\u003c/em\u003e34, 289\u0026ndash;295.\u003c/li\u003e\n\u003cli\u003eHardik, G., Vaibhav, B., Patel, N. M., Naeem, P.,Jatin, N and Ramachandran, B. (2013). Doxorubicin mediated Cardiotoxicity in rats: Protective role of felodipine on cardiac indice. Environmental Toxicology and Pharmacology, 36, 787\u0026ndash;795.\u003c/li\u003e\n\u003cli\u003eHashem, M. M., Abo-EL-Sooud, K., Abd-Elhakim, Y. M., Badr, Y. A. H., El-Metwally, A. E., \u0026amp; Bahy-El-Dien, A. (2020). The long-term oral exposure to titanium dioxide impaired immune functions and triggered cytotoxic and genotoxic impacts in rats. \u003cem\u003eJournal of Trace Elements in Medicine and Biology\u003c/em\u003e, \u003cem\u003e60\u003c/em\u003e, 126473. https://doi.org/10.1016/j.jtemb.2020.126473\u003c/li\u003e\n\u003cli\u003eHayyan, M., Hashim, M. A and Al Nashef, I. M. (2016). Superoxide Ion: Generation and Chemical Implications. Chemical Review. 116 (5): 3029\u0026ndash;385. \u003c/li\u003e\n\u003cli\u003eHenry, J. B. (1979). Clinical Diagnosis and Management by Laboratory Methods W.BSa under sand Company, Philadelphia, Page 365 (1979).\u003c/li\u003e\n\u003cli\u003eHoma, D., Haile, E and Washe, A. P. (2016). Determination of spatial chromium contamination of the environment around industrial zones. \u003cem\u003eInter Journal of Analytical Chemistry\u003c/em\u003e, Article ID 7214932. https://doi.org/10.1155/2016/7214932\u003c/li\u003e\n\u003cli\u003eHusain, N., \u0026amp; Mahmood, R. (2018). 3, 4-Dihydroxybenzaldehyde quenches ROS and RNS and protects human blood cells from Cr (VI)-induced cytotoxicity and genotoxicity. \u003cem\u003eToxicology in Vitro\u003c/em\u003e, \u003cem\u003e50\u003c/em\u003e, 293-304.\u003c/li\u003e\n\u003cli\u003eILAR (1986). Guide for the Care and Use of Laboratory Animals. Committee on Care and Use of Laboratory Animals, US Department of Health and Human Services, Public Health Service, Institute of Laboratory Animal Resources, USA.\u003c/li\u003e\n\u003cli\u003eIngbar, D. H. (2019). Cardiogenic pulmonary oedema: mechanisms and treatment-an intensivist\u0026apos;s view. \u003cem\u003eCurrent opinion in critical care\u003c/em\u003e, \u003cem\u003e25\u003c/em\u003e(4), 371-378. \u003c/li\u003e\n\u003cli\u003eJung, K., Nickel, E, \u0026amp; Pergande, M. (2000). A micro-albuminuria assay using bromphenol blue. \u003cem\u003eClinicaChimica Acta\u003c/em\u003e, \u003cem\u003e187\u003c/em\u003e, 163-172.\u003c/li\u003e\n\u003cli\u003eKarabulut, D., Ozturk, E., Kaymak, E., Akin, A.T., Yakan, B. (2020).Thymoquinone attenuates doxorubicin‐cardiotoxicity in rats. \u003cem\u003eJournal of Biochemical and Molecular Toxicology,\u003c/em\u003e 20s20(e22618), 1-9\u003c/li\u003e\n\u003cli\u003eKurakula, K., Smolders, V. F., Tura-Ceide, O., Jukema, J. W., Quax, P. H., \u0026amp; Goumans, M. J. (2021). Endothelial dysfunction in pulmonary hypertension: cause or consequence?. \u003cem\u003eBiomedicines\u003c/em\u003e, \u003cem\u003e9\u003c/em\u003e(1), 57.\u003c/li\u003e\n\u003cli\u003eLakhani, H. V., Pillai, S. S., Zehra, M., Dao, B., Tirona, M. T., Thompson, E., \u0026amp; Sodhi, K. (2021). Detecting early onset of anthracyclines-induced Cardiotoxicity using a novel panel of biomarkers in West-Virginian population with breast cancer. \u003cem\u003eScientific Reports\u003c/em\u003e, \u003cem\u003e11\u003c/em\u003e(1), 1-11. doi: 10.1038/s41598-021-87209-8 \u003c/li\u003e\n\u003cli\u003eLee, J., Bae, E. H., Ma, S. K., \u0026amp; Kim, S. W. (2016). Altered nitric oxide system in cardiovascular and renal diseases. \u003cem\u003eChonnam Medical Journal\u003c/em\u003e, \u003cem\u003e52\u003c/em\u003e(2), 81-90. https://doi.org/10.4068/cmj.2016.52.2.81 \u003c/li\u003e\n\u003cli\u003eLogan, D., Rubayat, R., Mohamed, E., Pablo, P., Nugent,K., (2019). Cardiogenic Pulmonary Oedema, \u003cem\u003eAm J Med Sci., 358\u003c/em\u003e(6),389-397. doi: 10.1016/j.amjms.2019.09.011. \u003c/li\u003e\n\u003cli\u003eMagnussen, C. \u0026amp; Blankenberg, S. (2018). Biomarkers for heart failure: small molecules with high clinical relevance. \u003cem\u003eJournal of internal medicine\u003c/em\u003e, \u003cem\u003e283\u003c/em\u003e(6), 530-543.\u003c/li\u003e\n\u003cli\u003eMatthay, M. A., Zemans, R. L., Zimmerman, G. A., Arabi, Y. M., Beitler, J. R., Mercat, A., ... \u0026amp; Calfee, C. S. (2019). Acute respiratory distress syndrome. \u003cem\u003eNature reviews Disease primers\u003c/em\u003e, \u003cem\u003e5\u003c/em\u003e(1), 1-22.\u003c/li\u003e\n\u003cli\u003eMehta, L. S., Watson, K. E., Barac, A., Beckie, T. M., Bittner, V., Cruz-Flores, S., Dent, S., Kondapalli, L., Ky, B., Okwuosa, T., Pi\u0026ntilde;a, I.L., Volgman, A. S. (2018). Cardiovascular disease and breast cancer: where these entities intersect: a scientific statement from the American Heart Association. \u003cem\u003eCirculation\u003c/em\u003e, \u003cem\u003e137\u003c/em\u003e(8), e30-e66. DOI: 10.1161/CIR.0000000000000556\u003c/li\u003e\n\u003cli\u003eMelanson, S. E.,Tanasijevic, M. J \u0026amp; Jarolim, P. (2007). Cardiac Troponin assay. \u003cem\u003eCirculation\u003c/em\u003e, \u003cem\u003e116\u003c/em\u003e(18), e501-504.\u003c/li\u003e\n\u003cli\u003eMladěnka, P., Applov\u0026aacute;, L., Patočka, J., Costa, V. M., Remiao, F., Pourov\u0026aacute;, J., Mladěnka, A., Karl\u0026iacute;čkov\u0026aacute;, J., Jahod\u0026aacute;ř, L., Vopr\u0026scaron;alov\u0026aacute;, M., Varner, K.J., \u0026Scaron;těrba, M., TOX‐OER and CARDIOTOX Hradec Kr\u0026aacute;lov\u0026eacute; Researchers and Collaborators. (2018). Comprehensive review of cardiovascular toxicity of drugs and related agents. \u003cem\u003eMedicinal research reviews\u003c/em\u003e, \u003cem\u003e38\u003c/em\u003e(4), 1332-1403. doi: 10.1002/med.21476 \u003c/li\u003e\n\u003cli\u003eMookerjee, A., Basu, J. M., Majumder, S., Chatterjee, S., Panda, G. S., Dutta, P., ... \u0026amp; Choudhuri, S. K. (2006). A novel copper complex induces ROS generation in doxorubicin resistant Ehrlich ascitis carcinoma cells and increases activity of antioxidant enzymes in vital organs in vivo. BMC cancer, 6(1), 1-11.\u003c/li\u003e\n\u003cli\u003eMorelli, M. B., Bongiovanni, C., Da Pra, S., Miano, C., Sacchi, F., Lauriola, M., \u0026amp; D\u0026rsquo;Uva, G. (2022). Cardiotoxicity of Anticancer Drugs: Molecular Mechanisms and Strategies for Cardioprotection. \u003cem\u003eFrontiers in Cardiovascular Medicine\u003c/em\u003e, \u003cem\u003e9\u003c/em\u003e. https://doi.org/10.3389/fcvm.2022.847012.\u003c/li\u003e\n\u003cli\u003eMoreno-Gonzalez, G., \u0026amp; Toapanta-Gaibor, N. D. (2022). \u003cem\u003eNon Invasive Ventilation in Acute Cardiac Pulmonary Oedema\u003c/em\u003e. In Teaching Pearls in Noninvasive Mechanical Ventilation (pp. 305-314). Springer, Cham.\u003c/li\u003e\n\u003cli\u003eNavya, K., Phani, K.G., Chandrasekhar, Y., Anilakumar, Kr. (2018) Evaluation of Potassium Dichromate (K2Cr2O7)-Induced Liver Oxidative Stress and Ameliorative Effect of Picrorhiza kurroa Extract in Wistar Albino Rats. Biological Trace Element Research \u003cem\u003e184\u003c/em\u003e(1):154-164. doi: 10.1007/s12011-017-1172-2. \u003c/li\u003e\n\u003cli\u003eNIOSH (2013). Criteria for a recommended standard occupational exposure to hexavalent chromium. CDC - US Department of Health and Human Services and Centers for Disease Control and Prevention NIOSH - National Institute for Occupational Safety and Health. 168.\u003c/li\u003e\n\u003cli\u003eNur-E-Alam, M., Mia, M. A. S, Ahmad, F and Rahman, M. M.(2020).An overview of Chromium removal techniques from tannery effluents. Appl Water Sci. 10,205.\u003c/li\u003e\n\u003cli\u003e\u003cem\u003eOffice of Environmental Health Hazard Assessment\u003c/em\u003e (OEHHA). (2009) Evidence on the developmental and reproductive toxicity of chromium (hexavalent compounds). Reproductive and Cancer Hazard Assessment Section. Office of Environmental Health Hazard Assessment. 977.\u003c/li\u003e\n\u003cli\u003eOnyedikachi, U. B., Achi, N. K., Oriaku, C. E. \u0026amp; Onyeabo, C. (2019a).Health risk assessment of heavy metal contamination of some indigenous vegetables grown in oil spilled agricultural area in Ogoniland, rivers state, Nigeria. \u003cem\u003eNigerian Agricultural Journal\u003c/em\u003e, \u003cem\u003e52\u003c/em\u003e(1),138-151.\u003c/li\u003e\n\u003cli\u003eOnyedikachi, U. B.,Belonwu, D. C and Wegwu, O. M. (2018). Human health risk assessment of heavy metals in soils and commonly consumed food crops from quarry sites located at Isiagwu, Ebonyi State.\u003cem\u003eOvidius University Annals of Chemistry,\u003c/em\u003e 29, 8-24. https://doi.org/10.2478/auoc-2018-0002\u003c/li\u003e\n\u003cli\u003eOnyedikachi, U. B.,Belonwu, D. C and Wegwu, O. M. (2019b). Health risk assessment of Chromium, Manganese and Arsenic through the consumption of food from Industralized areas in South Eastern, Nigeria. \u003cem\u003eAnnual Research and Review in Biology\u003c/em\u003e, 31(6), 1 - 20.\u003cstrong\u003e DOI:\u003c/strong\u003e 10.9734/arrb/2019/v31i630067\u003c/li\u003e\n\u003cli\u003ePagilia, D.E., \u0026amp; Valentine, W N. (1967). Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. \u003cem\u003eJournal of Laboratory and Clinical Medicine\u003c/em\u003e, \u003cem\u003e70,\u003c/em\u003e158-69. .https://doi.org/10.5555/URI:PII:0022214367900765\u003c/li\u003e\n\u003cli\u003ePaone, G., De Rose, G., Giudice, G. C., \u0026amp; Cappelli, S. (2018). Physiology of pleural space after pulmonary resection. \u003cem\u003elung\u003c/em\u003e, \u003cem\u003e17\u003c/em\u003e, 20.\u003c/li\u003e\n\u003cli\u003ePark, K. C., Gaze, D. C., Collinson, P. O., \u0026amp; Marber, M. S. (2017). Cardiac troponins: from myocardial infarction to chronic disease. \u003cem\u003eCardiovascular research\u003c/em\u003e, \u003cem\u003e113\u003c/em\u003e(14), 1708-1718.\u003c/li\u003e\n\u003cli\u003ePokhrel, G. R., \u0026amp; Pokhre, G. (2022). The Effect of Chromium on Human-Health: A Review. \u003cem\u003eBMC Journal of Scientific Research\u003c/em\u003e, \u003cem\u003e5\u003c/em\u003e(1), 27-35.\u003c/li\u003e\n\u003cli\u003ePrasad, S., Yadav, K. K., Kumar, S., Gupta, N., Cabral-Pinto, M. M., Rezania, S., ... \u0026amp; Alam, J. (2021). Chromium contamination and effect on environmental health and its remediation: A sustainable approaches. \u003cem\u003eJournal of Environmental Management\u003c/em\u003e, \u003cem\u003e285\u003c/em\u003e, 112174. DOI: 10.1016/j.jenvman.2021.112174\u003c/li\u003e\n\u003cli\u003eRadwan, R. R., Shaban, E. A., Kenawy, S. A., \u0026amp; Salem, H. A. (2012). \u003cem\u003eProtection by low-dose \u0026gamma; radiation on doxorubicin-induced nephropathy in rats pretreated with curcumin, green tea, garlic or l-carnitine.\u003c/em\u003e Bulletin of Faculty of Pharmacy, Cairo University, 50(2), 133-140.\u003c/li\u003e\n\u003cli\u003eReitman, S. \u0026amp; Frankel, S. (1975). Acolorimetric method for the determination of serum glutamic oxaloacetic and glutamic pyruvic transaminases. \u003cem\u003eAmerican Journal of Clinical Pathology\u003c/em\u003e, \u003cem\u003e28\u003c/em\u003e, 56-63.\u003c/li\u003e\n\u003cli\u003eRemy, L. L., \u0026amp; Clay, T. (2014). Longitudinal analysis of health outcomes after exposure to toxics, Willits California, 1991\u0026ndash;2012: application of the cohort-period (cross-sequential) design. \u003cem\u003eEnvironmental Health\u003c/em\u003e, \u003cem\u003e13\u003c/em\u003e(1), 1-11. https://doi.org/10.1186/1476-069X-13-88 \u003c/li\u003e\n\u003cli\u003eSandamali, J. A. N., Hewawasam, R. P., Jayatilaka, K. A. P. W., Mudduwa, L. K. B. (). Dose dependent cardiac effects of Doxorubicin in wistar rats: A Biochemical and histopathological analysis. \u003cem\u003eInternational Journal of Pharmaceutical Sciences and Research\u003c/em\u003e, \u003cem\u003e10\u003c/em\u003e(6), 2700-2710. DOI: 10.13040/IJPSR.0975-8232.10(6).2700-10 \u003c/li\u003e\n\u003cli\u003eSharifi-Rad, M., Anil Kumar, N. V., Zucca, P., Varoni, E. M., Dini, L., Panzarini, E., Rajkovic, J., Fokou, P.V.T., Azzini, E., Peluso, I., Mishra, A.P., Nigam, M., El Rayess, Y., El Beyrouthy, M., Polito, L., Iriti, M., Martins N., Martorell, M., Docea, A.O., Setzer, W.N., Calina, D., Cho, W.C., Sharifi-Rad, J. (2020). Lifestyle, oxidative stress, and antioxidants: back and forth in the pathophysiology of chronic diseases. Frontiers in physiology, 11, 694. https://doi.org/10.3389/fphys.2020.00694 \u003c/li\u003e\n\u003cli\u003eSilva-Costa-Gomes, T., Gallart, L., Valles, J., Trillo, L., Minguella, J., \u0026amp; Puig, M. M. (2005). Low-vs high-dose almitrine combined with nitric oxide to prevent hypoxia during open-chest one-lung ventilation. \u003cem\u003eBritish journal of anaesthesia\u003c/em\u003e, \u003cem\u003e95\u003c/em\u003e(3), 410-416. https://doi.org/10.1093/bja/aei194 \u003c/li\u003e\n\u003cli\u003eSinha, K.A. (1972). Colorimetric Assay of Catalase. \u003cem\u003eAnnals of Biochemistry\u003c/em\u003e, \u003cem\u003e47,\u003c/em\u003e389\u0026ndash;394.\u003c/li\u003e\n\u003cli\u003eSoudani, N. A, AfefTroudi, A. L., HanenB. A. L.,Ibtissem, B.A.Tahia, B. B andNajiba, Z. (2011). Cardioprotective effects of selenium on chromium(VI)-induced toxicity infemalerats . Ecotoxicology and Environmental Safety, 74, 513\u0026ndash;520.\u003c/li\u003e\n\u003cli\u003eTabassum, S., Gangarapu, K., Thumma, G., Manda, S., \u0026amp; Anreddy, R. N. R. (2014). Cardioprotective activity of,-Bis [5-methyl-2-oxo-1, 2-dihydro-3H-indol-3-ylidene] carbonohydrazide Derivative against Doxorubicin Induced Cardiotoxicity in Rats. \u003cem\u003eJournal of Chemistry.\u003c/em\u003e2014:1-7 https://doi.org/10.1155/2014/260672\u003c/li\u003e\n\u003cli\u003eTeraoka, K., Hirano, M., Yamaguchi, K and Yamashina, A. (2000). Progressive cardiac dysfunction in adriamycin-induced cardiomyopathy rats. \u003cem\u003eEuropean Journal of Heart Failure, 2\u003c/em\u003e, 373 \u0026ndash;378. \u003c/li\u003e\n\u003cli\u003eTran, N., Garcia, T., Aniqa, M., Ali, S., Ally, A., \u0026amp; Nauli, S. M. (2022). Endothelial Nitric Oxide Synthase (eNOS) and the Cardiovascular System: in Physiology and in Disease States. \u003cem\u003eAmerican journal of biomedical science \u0026amp; research\u003c/em\u003e, \u003cem\u003e15\u003c/em\u003e(2), 153\u0026ndash;177.\u003c/li\u003e\n\u003cli\u003eVandenberg, R.J., Ryan, R.M. Carland, J.E., Imlach, W.L., Macdonald, J.C. (2014). GlycineTransport Inhibitor for the treatment of pain. Trends in pharmaceutical Sciences, 35(8),423-430. https://doi.org/10.1016/j.tips.2014.05.006 \u003c/li\u003e\n\u003cli\u003eVulesevic, B., Lavoie, S. S., Neagoe, P. E., Dumas, E., R\u0026auml;kel, A., White, M., \u0026amp; Sirois, M. G. (2019). CRP induces NETosis in heart failure patients with or without diabetes. \u003cem\u003eImmunoHorizons\u003c/em\u003e, \u003cem\u003e3\u003c/em\u003e(8), 378-388.\u003c/li\u003e\n\u003cli\u003eWagner, G.S., Roe, C.R.,Limbird, L. E., Rosati, R. A and Wallace, A. G. (2003). The importance of identification of the myocardial-specific isoenzyme of creatine phosphokinase (MB form) in the diagnosis of acute myocardial infarction. \u003cem\u003eCirculation,\u003c/em\u003e \u003cem\u003e47\u003c/em\u003e, 263-269.\u003c/li\u003e\n\u003cli\u003eWallin, B., Rosengren, B.,Shertzer, H. G and Camejo G (1993). Lipoprotein oxidation and measurement of TBARS formation in single microlitre plate; it\u0026apos;s use for evaluation of antioxidants. \u003cem\u003eAnalytical Biochemistry\u003c/em\u003e, \u003cem\u003e208\u003c/em\u003e, 10-15.\u003c/li\u003e\n\u003cli\u003eWu, B. B., Leung, K. T., \u0026amp; Poon, E. N. (2022). Mitochondrial-Targeted Therapy for Doxorubicin-Induced Cardiotoxicity. \u003cem\u003eInternational journal of molecular sciences\u003c/em\u003e, \u003cem\u003e23\u003c/em\u003e(3), 1912. https://doi.org/10.3390/ijms23031912 \u003c/li\u003e\n\u003cli\u003eWu, Y., Ding, Y., Ramprasath, T., \u0026amp; Zou, M. H. (2021). Oxidative stress, GTPCH1, and endothelial nitric oxide synthase uncoupling in hypertension. \u003cem\u003eAntioxidants \u0026amp; redox signaling\u003c/em\u003e, \u003cem\u003e34\u003c/em\u003e(9), 750-764. DOI: 10.1089/ars.2020.8112\u003c/li\u003e\n\u003cli\u003eWuri, L., Arosh, J. A., Wu, J. Z., \u0026amp; Banu, S. K. (2022). Exposure to hexavalent chromium causes infertility by disrupting cytoskeletal machinery and mitochondrial function of the metaphase II oocytes in superovulated rats. \u003cem\u003eToxicology Reports\u003c/em\u003e, \u003cem\u003e9\u003c/em\u003e, 219-229. https://doi.org/10.1016/j.toxrep.2022.02.002 \u003c/li\u003e\n\u003cli\u003eYang, F., Teves, S.S., Kemp, C.J., Henikoff,, S. (2014). Doxorubicin, DNA torsion, and chromatin dynamics. \u003cem\u003eBiochim. Biophys. Acta.\u003c/em\u003e, \u003cem\u003e1845\u003c/em\u003e, 84\u0026ndash;89. https://doi.org/10.1016/j.bbcan.2013.12.002 \u003c/li\u003e\n\u003cli\u003eYokota, T., \u0026amp; Kinugawa, S. (2021). Premedication with pioglitazone prevents doxorubicin-induced left ventricular dysfunction in mice. \u003cem\u003eBMC Pharmacology and Toxicology\u003c/em\u003e, 22, 27. https://doi.org/10.1186/s40360-021-00495-w \u003c/li\u003e\n\u003cli\u003eZhai, Q., Gong, X., Wang, C., Zhao, J., Zhang, H., Tian, F., \u0026amp; Chen, W. (2019). Food-borne patulin toxicity is related to gut barrier disruption and can be prevented by docosahexaenoic acid and probiotic supplementation. \u003cem\u003eFood \u0026amp; function\u003c/em\u003e, \u003cem\u003e10\u003c/em\u003e(3), 1330-1339.\u003c/li\u003e\n\u003cli\u003eZompatori, M., Ciccarese, F., \u0026amp; Fasano, L. (2014). Overview of current lung imaging in acute respiratory distress syndrome. \u003cem\u003eEuropean respiratory review\u003c/em\u003e, \u003cem\u003e23\u003c/em\u003e(134), 519-530.\u003c/li\u003e\n\u003cli\u003ePokhrel, G. R., \u0026amp; Pokhre, G. (2022). The Effect of Chromium on Human-Health: A Review. \u003cem\u003eBMC Journal of Scientific Research\u003c/em\u003e, \u003cem\u003e5\u003c/em\u003e(1), 27-35.\u003c/li\u003e\n\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":true,"hideJournal":true,"highlight":"","institution":"Michael Okpara University of Agriculture","isAcceptedByJournal":false,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":" Chromium 6+, Cardiotoxicity, Doxorubicin, Potassium dichromate","lastPublishedDoi":"10.21203/rs.3.rs-2847266/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-2847266/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003eDoxorubicin (Dox) is cardiotoxicity is established while chromium 6\u003csup\u003e+\u003c/sup\u003e compound (Cr[VI]) could be cardiotoxic due to its bioaccumulation capacity. This study compared vehicle, dose, and duration-related oxidative, cardiotoxic, inflammatory and histologic responses of Cr[VI] and Dox intoxication in rats\u0026rsquo; heart by standard protocols. The rats were respectively intoxicated with Cr [VI] and Dox in 3 different phases. In the first phase, sixty rats were assigned to six groups of ten each. Group 1 served as the Control while groups 2, 3, and 4 were treated with oral doses of 10, 20, and 30 mg/kg body weight (b.wt) of K\u003csub\u003e2\u003c/sub\u003eCr\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e7\u003c/sub\u003e (Cr[VI]) solution while groups 5 and 6 received intraperitoneal administration of 15 and 20 mg/kg b.wt Dox for two days, respectively, before the sacrifice. The procedure was repeated in the second and third Phases, but for 60 days. Oxidative, cardiotoxic, inflammatory and histologic indices were determined in the rats\u0026rsquo; heart. The results indicated that exposure to either Dox or Cr{VI] caused a significant (\u003cem\u003eP\u003c/em\u003e\u0026thinsp;\u0026lt;\u0026thinsp;0.05) dose, vehicle and duration-dependent decrease in Superoxide dismutase (SOD), Glutathione peroxidase (GPx), Catalase (CAT) activities and Nitric Oxide(NO) levels but an increase in Cardiac Troponin (CTnI) levels, Creatinine-kinase (CK-MB), C-reactive protein(CRP), Aspartate-transaminase(AST), Lactate-dehydrogenase (LDH) and Malondialdehyde (MDA) compared to the control. Heart histopathology of Dox- and Cr[VI] treated rats showed dose, vehicle and duration-dependent pulmonary oedema, hyaline necrosis and displacement of adjacent myocytes compared to control. Thus, Cr[VI] compared well with Dox in cardiotoxicity induction accompanied with oxidative stress, inflammatory and histo-hepatic responses in the rats\u0026rsquo; heart.\u003c/p\u003e \u003cp\u003e \u003c/p\u003e","manuscriptTitle":"Comparative Evaluation of Vehicle, Dose, and Duration-related Oxidative, Cardiotoxic, Inflammatory and Histologic Responses of Chromium 6+ and Doxorubicin in Rats’ Heart","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2023-04-25 22:37:22","doi":"10.21203/rs.3.rs-2847266/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"f258fab3-233a-492a-a0ef-d2ae1d2027c5","owner":[],"postedDate":"April 25th, 2023","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"posted","subjectAreas":[{"id":20984923,"name":"Toxicology"}],"tags":[],"updatedAt":"2023-04-25T22:37:22+00:00","versionOfRecord":[],"versionCreatedAt":"2023-04-25 22:37:22","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-2847266","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-2847266","identity":"rs-2847266","version":["v1"]},"buildId":"FbvkV6FR0MCFSLy54lSbu","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}